A spontaneous mutation in kdsD, a biosynthesis gene for 3 Deoxy-D-manno-Octulosonic Acid, occurred in a ciprofloxacin resistant strain of Francisella tularensis and caused a high level of attenuation in murine models of tularemia

Taylor Chance1*, Jennifer Chua2, Ronald G. Toothman2, Jason T. Ladner3, Jonathan E. Nuss4, Jo Lynne Raymond1, Fabrice V. Biot5, Samandra Demons2, Lynda Miller2, Stephanie Halaschoris2, Sherry Mou2, Galina Koroleva3, Sean Lovett3, Gustavo Palacios3, Nicholas J. Vietri5, Patricia L. Worsham2, Christopher K. Cote2, Todd M. Kijek4, Joel A. Bozue**

1 Pathology Division, United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, Frederick, MD, United States of America, 2 Bacteriology Division, USAMRIID, Fort Detrick, Frederick, MD, United States of America, 3 Center for Genome Sciences, USAMRIID, Fort Detrick, Frederick, MD, United States of America, 4 Department of Molecular and Translational Sciences, USAMRIID, Fort Detrick, Frederick, MD, United States of America, 5 Institut de Recherche Biomédicale des Armées, Département de Biologie des Agents Transmissibles, Unité de Bactériologie/UMR_MD1, B.P. 73, Brétigny-sur-Orge, France

Current address: Veterinary Pathology Services, Joint Pathology Center, Silver Spring, MD United States of America

* joel.a.bozue.civ@mail.mil

Abstract

Francisella tularensis, a gram–negative facultative intracellular bacterial pathogen, is the causative agent of tularemia and able to infect many mammalian species, including humans. Because of its ability to cause a lethal infection, low infectious dose, and aerosolizable nature, F. tularensis subspecies tularensis is considered a potential biowarfare agent. Due to its in vitro efficacy, ciprofloxacin is one of the antibiotics recommended for post-exposure prophylaxis of tularemia. In order to identify therapeutics that will be efficacious against infections caused by drug resistant select-agents and to better understand the threat, we sought to characterize an existing ciprofloxacin resistant (CipR) mutant in the Schu S4 strain of F. tularensis by determining its phenotypic characteristics and sequencing the chromosome to identify additional genetic alterations that may have occurred during the selection process. In addition to the previously described genetic alterations, the sequence of the CipR mutant strain revealed several additional mutations. Of particular interest was a frameshift mutation within kdsD which encodes for an enzyme necessary for the production of 3-Deoxy-D-manno-Octulosonic Acid (KDO), an integral component of the lipopolysaccharide (LPS). A kdsD mutant was constructed in the Schu S4 strain. Although it was not resistant to ciprofloxacin, the kdsD mutant shared many phenotypic characteristics with the CipR
mutant, including growth defects under different conditions, sensitivity to hydrophobic agents, altered LPS profiles, and attenuation in multiple models of murine tularemia. This study demonstrates that the KdsD enzyme is essential for Francisella virulence and may be an attractive therapeutic target for developing novel medical countermeasures.

**Introduction**

*Francisella tularensis* is a gram-negative bacterium that causes the life threatening and debilitating disease tularemia. As a facultative intracellular pathogen, its ability to replicate within various host cells, such as macrophages, dendritic cells, neutrophils, and epithelial cells is well documented and essential for virulence [1–13]. *F. tularensis* is able to infect a wide range of animal species, including humans. *F. tularensis* can be transmitted to humans through a number of routes; the most common being the bite of an infected insect or other arthropod vector [14–17]. Human illness can range from the ulceroglandular form to more serious pneumonic or typhoidal tularemia [15]. In pneumonic tularemia, infection progresses from the lungs to other organs, primarily the liver and spleen [18–23]. The risk of infection is associated mainly with two subspecies, the more virulent *F. tularensis* ssp. *tularensis* (type A) and the less virulent *F. tularensis* ssp. *holarctica* (type B).

Due to its high pathogenicity, low infectious dose, and aerosizable nature, *F. tularensis* poses a serious potential threat for use as a biological weapon and therefore is classified by the US Department of Health and Human Services as a Tier 1 Select Agent [18, 20, 24, 25]. This threat is of even greater concern with the potential for development of antibiotic resistant strains of Francisella which has previously been demonstrated [26–28].

One of the major virulence factors of *Francisella* is lipopolysaccharide (LPS) which plays an important role in evasion of the host immune responses [29–33]. LPS is the major outer surface structure of gram-negative bacteria and consists of three components: lipid A, a polysaccharide core, and the O-antigen polysaccharide [34]. The core region of the LPS is linked to lipid A by 3-Deoxy-D-manno-Octulosonic Acid (KDO), an eight carbon sugar. The LPS of *F. tularensis* does not bind to the LPS binding protein or activate the Toll-like-receptor (TLR) 4 signaling pathway [35, 36]. In contrast, lipid A moieties from other gram-negative bacteria are able to interact with the TLR4, activating the innate immune system to stimulate a strong proinflammatory response [30, 36–38]. The inertness of *F. tularensis* LPS is speculated to be due to the atypical lipid A structure that is distinct from other gram-negative bacteria. Specifically, *F. tularensis* lipid A is asymmetrical and tetraacylated, possesses longer length fatty acid chains, lacks phosphate substituents, and contains a unique amino sugar moiety [29, 31, 34, 39–42].

The traditional therapy for tularemia is streptomycin, tetracycline, or doxycycline [19, 43–46]. However, the fluorinated quinolone, ciprofloxacin, may offer advantages as a first-line therapy of treatment of tularemia and is recommended as an acceptable treatment option for *F. tularensis*, particularly after an aerosol exposure resulting from the use as a biological weapon [18, 47–53]. The advantages for the use of ciprofloxacin over other antibiotics are the bactericidal effects, the potential for oral administration, and demonstrated *in vitro* activity [45, 54, 55]. Ciprofloxacin targets the bacterial type II enzymes, DNA gyrase (GyrA and GyrB) and topoisomerase IV (ParC and ParE) [56–59] and functions by stabilizing an intermediate stage of the DNA replication reaction thus inhibiting cell division [58, 60, 61]. Resistance to ciprofloxacin is caused by changes to the amino acid sequences around the enzyme active site resulting in reduced drug affinity and continued gyrase/topoisomerase activity thereby allowing for continued bacterial cell growth [58, 59].
In a previous study, a *F. tularensis* ciprofloxacin resistant (CipR) mutant of Schu S4 was generated by serially passaging on increasing concentrations of the antibiotic [26]. The CipR mutant contained two non-synonymous substitutions in *gyrA* and a five base pair (bp) deletion in *parE*. In the current study, we further characterized the phenotype of the Schu S4 CipR mutant and, more importantly, determined if this strain retained virulence. The genome was sequenced to identify other genetic alterations which occurred during the selection process, excluding those previously described to *gyrA* and *parE*. Interestingly, one of the other mutations to the CipR mutant strain was a frameshift in the *kdsD* gene which encodes for D-arabino-bose 5-phosphate isomerase. KdsD is an enzyme that catalyzes the conversion of the pentose pathway intermediate D-ribose 5-phosphate (R5P) into D-arabinose 5-phosphate (A5P) [62]. A5P is a precursor of KDO, an integral part of the LPS, in which the lipid A-KDO molecule serves as a linker for the O-antigen polysaccharide [38]. As LPS is known to be an important virulence factor for *F. tularensis* [63–68], we sought to determine if the mutation of the *kdsD* gene led to many of the characteristics observed for the CipR mutant strain, such as the lack of an O-antigen and loss of virulence in various murine models of tularemia. We found that many of the phenotypes observed with the *kdsD* mutant were similar to those of CipR mutant.

**Materials and methods**

**Bacterial strains**

All strains and plasmids used in this study are listed in Table 1. *Escherichia coli* NEB Turbo cells (New England Biolabs) were used for cloning purposes. *E. coli* was propagated in Luria broth or agar supplemented with ampicillin at 100 μg/ml, hygromycin at 200 μg/ml, or kanamycin at 20 μg/ml as necessary. All cultures were grown at 37°C.

The *F. tularensis* subsp. *tularensis* strains used included the fully virulent Schu S4 [23] and the CipR mutant Schu S4 derivative [26] which had been previously selected with approval by the Centers for Disease Control. Previous characterization of the CipR mutant strain determined that the *gyrA* gene contained two base pair (bp) substitutions: C248→T and G259→T. In addition, a five-bp deletion occurred in the *parE* gene. Also included in the current study was *F. tularensis* subsp. *novicida* strain U112 and a transposon derivate [69] (BEI).

For routine growth of *F. tularensis* species, bacteria were grown on enriched chocolate agar plates obtained from Remel™ (product number R01300; Lenexa, KS). When necessary, agar was supplemented with ampicillin at 10 μg/ml, hygromycin at 200 μg/ml, or kanamycin at 20 μg/ml as necessary. All cultures were grown at 37°C.

Genomic sequencing and analysis

Genomic DNA was prepared from the ciprofloxacin resistant *F. tularensis* using the Qiagen Genomic-tip 500/G kit with the appropriate buffers according to the manufacturer’s instructions. DNA was sequenced on a Pacific Biosciences RSII. Specifically, the sequencing library was prepared using the SMRTbell™ Template Prep Kit (Pacific Biosciences, Menlo Park, CA) following manufacturer’s protocol. DNA (5 μg) was fragmented using gTUBE (Covaris Inc., Woburn, MA) to ~20 kb. After DNA damage repair and ends repair, blunt hairpin adapters were ligated to the template, and failed ligation products were digested with ExoIII and ExoVII exonucleases. Resulting SMRTbell template was size selected on BluePippin system (Sage Science, Beverly, MA) using 0.75% dye-free agarose cassette with 4–10kb Hi-Pass protocol and
low cut set on 4 kb. Size selected template was cleaned and concentrated with AMPure PB beads. The P4 polymerase was used in combination with the C2 sequencing kit and we collected 240-minute movies. Raw reads were quality filtered (subread length \(> 500\); polymerase read quality \(> 0.80\)) and assembled using HGAP 2 v2.1.0 with a length cutoff of 14,211 bp [73]. Gepard v1.30 [74] was used to identify repetitive, low-quality sequence at the contig ends, which was trimmed using custom scripts. The final genome assembly (Genbank: CP013853) was annotated using NCBI’s Prokaryotic Genome Annotation Pipeline v3.0 [75].

To identify genomic differences in \(F.\) \(tularensis\) CipR mutant relative to its parent strain, wgsim (github.com/lh3/wgsim) was used to computationally “shred” the \(de\) \(novo\) assembly into 1 million perfect-match read pairs (150bp x 2 with a fragment size of 500bp), for an average of \(~150x\) depth. These synthetic reads were then aligned to the \(F.\) \(tularensis\) Schu S4 reference genome (Genbank: NC_006570) using Bowtie2 (reads were ignored if they mapped equally well to multiple places in the reference genome) [76] and variants were called using the UnifiedGenotyper in GATK v3.1-1-g07a4bf8 [77]. The predicted effects of variants were annotated with SnpEff [78] using the “Francisella_tularensis_SCHU_S4_uid57589” database.

### Mutant construction

The \(kdsD::ltrB1\), mutant strain of \(F.\) \(tularensis\) were created using a modified TargetTron (Sigma-Aldrich, St. Louis, MO) mutagenesis system [70]. In brief, the coding sequence of the gene of interest was entered into the Sigma TargetTron primer design site to determine the appropriate oligonucleotides for retargeting the intron. The modification to this procedure was an \(XhoI\) restriction site was substituted for the \(HindIII\). The resulting PCR product was cloned into vector pKEK1140 [70]. The plasmid was introduced into the Schu S4 strain by

| Bacterial strains and plasmids | Relevant Characteristics | Reference/ Source |
|--------------------------------|--------------------------|-------------------|
| \(E.\) \(coli\) NEB Turbo | Cloning strain | NEB |
| \(F.\) \(tularensis\) Schu S4 | Fully virulent Type A strain | USAMRIID collection |
| CipR (Fl-127) | 2 bp substitutions in \(gyrA\) and a 5 bp deletion in \(parE\); ciprofloxacin resistant | [26] |
| \(kdsD::ltrB1\) | Inactivated \(kdsD\) | This study |
| \(kdsD::ltrB1\), with pMP831+\(kdsD\) | Complemented \(kdsD\) mutant strain | This study |
| \(F.\) \(novicida\) U112 strain | \(F.\) \(tularensis\) subsp. novicida | ATCC 15482 [15] |
| \(kpsF::T20\) | Inactivated \(kpsF\) (BEI catalog # NR-6746) | BEI [69] |
| \(kpsF::T20\) with pMP831+\(kdsD\) | Complemented \(kpsF::T20\) | This study |
| **MIC analysis strains** | | |
| \(E.\) \(coli\) ATCC 25922 | Used as a standard for MIC quality control | ATCC |
| \(S.\) \(aureus\) ATCC 29213 | Used as a standard for MIC quality control | ATCC |
| \(P.\) \(aeruginosa\) ATCC 27853 | Used as a standard for MIC quality control | ATCC |
| **Plasmids** | | |
| pKEK1140 | Targetron plasmid | [70] |
| pKEK1140-\(kdsD\) | pKEK1140-tgt \(kdsD\) gene | This study |
| pMP831 | Complementation plasmid | [71] |
| pMP831+\(kdsD\) | Plasmid containing the intact \(Ft\) \(kdsD\) gene | This study |

MIC, minimum inhibitory concentration

https://doi.org/10.1371/journal.pone.0174106.t001
electroporation and the transformed strains with the retargeted plasmid were grown at 30°C on chocolate agar with 10 μg/ml kanamycin. Kanamycin resistant colonies were then isolated and screened via PCR to identify mutant strains (Table 2). The presence of the TargeTron insertion was determined using an intron-specific EBS universal primer combined with a gene specific primer, and intron insertion of the targeted gene was determined using gene-specific primers that amplified across the insertion site (Table 2). To cure the plasmid from the mutant clones, bacteria were grown overnight at 39°C in BHI containing 1% Isovitalex and serially diluted on chocolate agar plates. Individual colonies were screened for loss of the pKEK1140 by PCR analysis (Table 2) and sensitivity to kanamycin (present on pKEK1140).

Complementation of the kdsD mutation

For complementing the observed phenotypes from the kdsD::ltrB1 L. tularis and kpsF::T20 F. novicida mutant strains, a functional kdsD gene was PCR amplified from DNA from the Schu S4 strain with flanking upstream DNA which would presumably contains the promoter. The DNA fragment was cloned into vector pMP831 [71] and then transformed into the respective mutant strains by electroporation. The constructs were selected by hygromycin resistance (200 μg/ml) which is present on the vector.

Growth assays. Growth assays were performed in Chamberlains defined broth [72], with or without the addition of A5P (Sigma-Aldrich, product # A2013), as indicated. Assays were performed using an Infinite M200 Pro (Tecan; Männedorf, Switzerland) microplate reader in 96-well microtiter plates at 37°C with shaking. The OD_{600} was measured every 60 min. For all assays, F. tularis or F. novicida strains were grown for 24 h or 18 h chocolate agar plate, respectively, and then resuspended in broth medium to an equal OD_{600}. All samples were performed in quadruplicate and included medium controls to confirm sterility and for use as blanks to calculate the absorbance of the cultures.

Macrophage assays

J774A.1 cells, a murine macrophage-like cell line obtained from the American Type Culture Collection, were seeded (~2.5x10^5 cells/well) into 24-well plates and cultured 2 days (37°C, 5% CO₂) at which time the cells had formed confluent monolayers. The cells were maintained in Dulbecco’s Modified Eagle’s medium (D-MEM) containing high glucose, 10% heat-inactivated fetal bovine serum (FBS), plus 1.5 g/l sodium bicarbonate. For the intracellular assays, F. tularis or F. novicida was suspended in phosphate buffered saline (PBS) from a 24 h or 18 h plate, respectively, and then diluted 1:5 in tissue culture medium. The bacterial suspension was

Table 2. Oligonucleotides used in this study.

| Oligonucleotide         | Sequence                                      |
|------------------------|-----------------------------------------------|
| 611|612s-IBS     | AAAACTCGAGATAATTATCCTTAGCAGCCTTAGCTAGGAGGAGTCAT |
| 611|612s-EB S1d | CAGATTGTCACATATTGCTGTAACAGATAAGTTTACAT |
| 611|612s-EB S2  | TGAACGGATATTTTCTAGTGGATACGATAGGGTCT |
| kdsD 5' cloning        | CGGACCCGATTTGGAATTGTTTTCAT                   |
| kdsD 3' cloning        | CGGACCCGATTTGGAATTGTTTTCAT                   |
| Kan probe F            | TGCATGTTACTCACCAGCTG                        |
| Kan probe R            | TACAACCTATTTTATTTTCCTCG                     |

Bolded sequence corresponds to XhoI restriction enzyme site. Underlined sequence corresponds to BsrGI restriction site. Italics sequence corresponds to Rsal restriction enzyme site.

https://doi.org/10.1371/journal.pone.0174106.t002
added to the macrophages in 200 μl to achieve a multiplicity of infection (MOI) of ~100:1, and the MOI was confirmed from this suspension by serial dilutions and plating on chocolate agar plates. The bacteria and macrophages were allowed to coincubate for 2 h at 37°C with 5% CO₂. Next, the medium containing the extracellular bacteria was aspirated and replaced with fresh tissue culture medium supplemented with 25 μg/ml of gentamycin for an additional 2 h. After this incubation, samples from the tissue culture wells were washed three times with PBS. The monolayer was then lysed with 200 μl of sterile water, immediately scraped, and suspended in 800 μl of PBS. The suspension was serially diluted in PBS and plated onto chocolate agar plates. The remaining tissue culture wells were assayed for CFU recovery at the 24 h post-challenge time point as described above. Replicate data from three separate experiments were normalized for comparing strains by determining the difference in percent CFU recovery between the assayed 4h and 24 h time points.

To analyze the fate of the macrophages infected with Schu S4 strains, coverslips containing the J774A.1 cells were fixed with 4% formalin, permeabilized with PBS containing 0.025% saponin and then subjected to Wright Giemsa solution (Electron Microscopy Sciences, Hatfield, PA) for 10 min. Coverslips were washed 3x with PBS and mounted. Light microscopy was performed on the Zeiss Axio Observer Z1 equipped with an x 40 oil objective lens, AxioCam HRc camera and Zen-Blue edition 2011 software (Carl Zeiss Microimaging, Thornwood, NY).

For analysis of macrophages infected with F. novicida, coverslips were removed and placed in media containing 1 drop of Cell Event Caspase 3/7 green ready probes reagent (ThermoFisher Scientific; Waltham, MA) and incubated for 30 min. Confocal microscopy was performed on the Zeiss 700 Laser Scanning Microscopy System using Zen-Black Edition 2011 software (Carl Zeiss Microimaging, Thornwood, NY). Fluorescent and differential interference contrast (DIC) images were collected using the ×40 (numerical aperture: 1.3) oil objective lens with the pinhole set to 2 Airy unit.

**Analysis of bacterial cell extracts**

Whole-cell extracts were collected for protein and LPS analysis from plate grown F. tularensis and F. novicida strains. Cultures were prepared at equal colony forming unit (CFU) concentrations in PBS, lysed in gel loading buffer solution, and boiled for 30 min. Sterility of the extracts was confirmed. Proteins were fractioned on NuPage Novex 4–12% Bis-Tris gels. For western analysis, fractionated proteins were transferred onto a nitrocellulose membrane using an iBlot Gel Transfer Device. After transfer, the membranes were blocked with 1% skim milk in Tris Buffered Saline + Tween 20. F. tularensis samples were blotted with mouse monoclonal antibodies, anti-LPS (F6070-02X; US Biological; Salem, MA) or anti-capsule (11B7; [63]), at a dilution of 1:500. F. novicida samples were blotted with a mouse monoclonal antibody from cell culture supernatants with an anti-LPS antibody, Fn#13, (ImmunoPrecise Antibodies; Victoria BC, Canada) at a dilution of 1:100. The loading control antibody used for all analyses was rabbit polyclonal anti-E.coli GroEL (dilution of 1:2,000) (Enzo Life Sciences; Farmingdale, NY). Bands were visualized using 3,3′,5,5′-Tetramethylbenzidine Membrane Peroxidase substrate (Kirkegaard & Perry Laboratories, Inc; Gaithersburg, MD).

**Mass spectrometry analysis of lipid A**

LPS from F. tularensis strains was prepared using a LPS extraction kit (Catalog # 17141) from Intron Biotechnology. Sterility of the LPS preparations was confirmed. The samples were analyzed by matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry analysis using protocols developed by Zhou et al [79]. In short, 20 μl of each LPS
A ciprofloxacin resistant strain of *F. tularensis* is highly attenuated

Sample was mixed with 80 μl of methanol/chloroform in a glass vial, briefly vortexed and 1 μl of the solubilized sample spotted on a stainless steel target. Samples were allowed to air dry and 0.5 μl of matrix (10 mg/ml 2,5-dihydrobenzoic acid) was added to each spot. Samples were analyzed by MALDI-TOF mass spectrometry in reflector/negative ion mode using an Applied Biosystems 5800 instrument (Foster City, CA). The instrument was calibrated with low molecular weight standards (Bruker; Billerica, MA) and data were collected from 800 to 4000 (m/z) by manual “hot spot” searching and adjusting laser intensity to obtain optimum signal to noise for each sample. Each of the reported spectra is averages of 1000 laser shots.

**Minimum inhibitory concentration (MIC) susceptibility assays**

Ciprofloxacin was purchased from U.S. Pharmacopeia (Rockville, MD), made into 5 mg/mL stocks according to the CLSI guidelines (Clinical and Laboratory Standards Institute, 2013), and stored at -70 °C until use. Bacterial inoculums were prepared by suspending colonies into cation-adjusted Mueller-Hinton broth (CAMHB) from isolates grown aerobically at 35 °C on chocolate agar plates for 42–48 h. An inoculum was prepared to the density of a 0.5 McFarland and then diluted 1:100 with CAMHB to a bacterial cell density of ~10^6 CFU/ml. To each well of the 96-well plate, 50 μl of the adjusted dilution was added for a final inoculum of ~5 x 10^4 CFU/well. MICs were determined by the broth micro-dilution method in 96-well plates according to CLSI guidelines (M07-A10, June 2015). Ciprofloxacin was serially diluted two-fold in 50 μl of CAMHB. The antibiotic range tested was 0.03–64 μg/ml based on a final well volume of 100 μl after inoculation. Plates were incubated at 35 °C and MICs determined visually at 42–48 h. Quality control was established by using *E. coli* ATCC 25922, *Staphylococcus aureus* ATCC 29213, and *Pseudomonas aeruginosa* ATCC 27853 according to CLSI guidelines.

**In vitro susceptibility assays**

*F. tularensis* and *F. novicida* strains were suspended in PBS at an OD_{600} of ~ 0.2 and 100 μl aliquots were spread on chocolate agar plates. Sterile paper disks 10 mm in diameter were saturated in water, SDS (100 mg/ ml), Triton X-100 (5%), Tween 20 (5%), or polymyxin B (PMB) (10 mg/ ml), allowed to dry, and placed onto chocolate agar plates. For each study, three separate disks were prepared for each inhibitor and assessed by measuring the diameter of the zone of growth inhibition. The study was repeated three separate times.

**Animal challenges**

To determine the ability to cause infection, BALB/c mice (8–9 week-old and obtained from Charles River Laboratories; Frederick, MD) were challenged with *F. tularensis* or *F. novicida* in groups of 10 by various routes. For all methods of infection, the challenge doses were determined by serial dilutions in PBS and plating on chocolate agar. *Intradermal challenge*. Frozen *F. tularensis* stocks were streaked onto chocolate agar and incubated at 37 °C for 2 days. Next, a fresh chocolate agar plate was swabbed from the streak plate and grown for 24 h. Bacterial cells were harvested from the plate in PBS, and mice were challenged with 0.1 ml aliquots at various cell concentrations. *Intranasal challenge*. Mice were anesthetized with 150 μl of ketamine, acepromazine, and xylazine injected intramuscularly. The mice were then challenged by intranasal instillation with 50 μl of *F. tularensis* or *F. novicida* suspended in PBS from 24 h or 18 h, respectively, grown freshly from swabbed plate cultures. *Aerosol challenge*. For aerosol challenges, a 24 h swabbed plate was used to inoculate flasks containing 25 ml of BHI broth containing 1% Isovitalex at an approximate OD_{600} of 0.025. This medium was chosen for aerosol studies as it was previously shown to be more conducive for *Francisella* survival during aerosolization and improved spray factors [80]. The broth cultures were grown overnight at 37 °C.
A ciprofloxacin resistant strain of *F. tularensis* is highly attenuated

shaker at 150 rpm and adjusted for various challenge doses. Mice were exposed to *F. tularensis* using a dynamic 30-liter humidity-controlled Plexiglas whole-body exposure chamber and calculated inhaled doses were obtained as previously described [81]. For all challenge experiments, mice were monitored several times each day and mortality rates (or euthanasia when moribund) were recorded. *In vivo* dissemination. For a *F. tularensis* dissemination study, mice were challenged intranasally as described above with the indicated strains and doses. At specified time points after challenge, mice were then euthanized within a CO$_2$ chamber. The lungs and spleens were harvested, rinsed with PBS, weighed, and then homogenized in 1 ml of PBS in a disposable tissue grinder (Covidien; Mansfield, MA). The homogenates were then serially diluted and plated on to chocolate agar plates. For pathological analysis of the challenged mice over the course of the infection, additional mice (n = 3) were processed for histopathology as described below.

**Ethics statement**

Challenged mice were observed at least twice daily for 21 days for clinical signs of illness. Humane endpoints were used during all studies, and mice were humanely euthanized when moribund according to an endpoint score sheet. Animals were scored on a scale of 0–12: 0–3 = no clinical signs; 4–7 = clinical signs; increase monitoring; 8–12 = distress; euthanize. Those animals receiving a score of 8–12 were humanely euthanized by CO$_2$ exposure using compressed CO$_2$ gas followed by cervical dislocation. However, even with multiple checks per day, some animals died as a direct result of the infection.

Animal research at The United States Army Medical Research Institute of Infectious Diseases (USAMRIID) was conducted and approved under an Institutional Animal Care and Use Committee (USAMRIID IACUC) in compliance with the Animal Welfare Act, Public Health Service Policy, and other Federal statutes and regulations relating to animals and experiments involving animals. The facility where this research was conducted is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care, International and adheres to principles stated in the Guide for the Care and Use of Laboratory Animals, National Research Council, 2011.

**Pathology**

Postmortem tissues were collected from mice challenged with *F. tularensis*, fixed in 10% neutral buffered formalin, routinely processed, embedded in paraffin, and sectioned for hematoxylin and eosin (HE) staining. Tissues examined histopathologically included: nasal cavity, oropharyngeal cavity, salivary gland, brain, pituitary gland, eyes, external/middle/internal ear, submandibular lymph node, esophagus, trachea, lungs, heart, mediastinal lymph node, thyroid gland, thymus, liver, spleen, stomach, small intestine, large intestine, pancreas, mesenteric lymph node, adrenal gland, urinary bladder, uterus, ovary, and bone marrow. At least a single section of the above tissues were examined by a board certified veterinary pathologist and were subjectively graded on the severity of necrosis/inflammation: minimal (involving < 5% of the tissue), mild (involving 5–10% of the tissue), moderate (involving 11–25% of the tissue), marked (involving 26–50% of the tissue), or severe (involving > 50% of the tissue).

**Statistics**

For comparing data from the sensitivity to inhibitor and CFU recovery from macrophages, statistical significance (*p* < 0.05) was determined by the two-tailed Student *t* test. Growth analysis of bacterial strains in broth media was analyzed as previously described [82]. We used a logistic growth equation to fit the data as a function of maximum density, lag time, and maximum...
growth rate. LD$_{50}$ analysis was determined by the Bayesian probit analysis. Survival rates were compared between groups by Fisher exact tests with permutation adjustment for multiple comparisons using SAS Version 8.2 (SAS Institute Inc., SAS OnlineDoc, Version 8, Cary, N.C. 2000).

**Results**

The genome of the CipR mutant was sequenced and additional mutations were identified.

The CipR mutant was previously examined for mutations to genes that comprise the quinolone resistance-determining region, within which mutations frequently give rise to ciprofloxacin resistance [58, 59]. From the study by Loveless et al. [26], the CipR mutant was shown to contain two non-synonymous substitutions in $gyrA$ and a five bp deletion in $parE$. To determine if other mutations had occurred during in vitro passaging for selection of ciprofloxacin resistance, the entire genome of the CipR mutant was sequenced using high-throughput, single-molecule sequencing (GenBank: CP013853). This resulted in 113,394 polymerase reads with an average read length of 6,626 bp (126,205 subreads, avg. length of 5935 bp). The genome assembled into a single contig of 1,877,832 bp with 1787 CDS features, 10 rRNA genes and 38 tRNA genes. The assembly contained a single gap in the middle of one copy of the Francisella pathogenicity island [83]. This region is ~30 kb and nearly perfectly duplicated in F. tularensis Schu S4. However, both the full copy and partial copy of this region in our assembly are identical to the homologous regions in the parental strain.

In total, we identified 15 mutations in the CipR mutant genome compared to F. tularensis Schu S4 (Table 3). These included the three previously identified mutations in $gyrA$ and $parE$, four mutations in intergenic regions (1 SNP and 3 indels) and eight additional mutations spread across seven different protein coding genes (Table 3). Most of the coding mutations were single nucleotide polymorphisms (SNPs) leading to amino acid substitutions in $fabH$, $fabF$, $FTT_0807$, $FTT_0676$, and $FTT_1573$. The $fupA$ gene experienced a single base pair deletion at nucleotide 105 followed by a single base pair insertion at nucleotide 111.

| Protein | Gene | Function | Gene Size | Mutation and consequence* |
|---------|------|----------|-----------|---------------------------|
| YP_169795 | kdsD | Isomerization of Ru5P to Asp. | 987 bp | Addition of A at 174 bp. |
| YP_170322.1 | fabH | 3-oxoacyl-ACP synthase | 972 bp | C→T at 805 bp. Pro→Ser |
| YP_169814.2 | capA | Hypothetical poly-gamma-glutamate system protein | 1,576 bp | A→G at 2721 bp. Asp→Gly |
| YP_170326.1 | fabF | beta-ketoacyl-acylcarrier-protein synthase II | 1,638 bp | A→G at 934 bp. Ser→Gly |
| YP_169692.1 | Ftt0676 | conserved hypothetical membrane protein | 1,260 bp | A→G at 848 bp. Glu→Gly |
| YP_169915.1 | fupA | Utilize iron bound to siderophores and for siderophore-independent iron acquisition | 1,728 bp | Deletion of G at 105 bp; addition of G at 111 bp. Pro→Leu |
| YP_170495.1 | ftaG | Hypothetical/ Surface antigen variable number repeat | 2,379 bp | C→T at 1517 bp. Thr→Ile. |

* Bp numbers corresponds to ATG = 1.

https://doi.org/10.1371/journal.pone.0174106.t003
which maintained the reading frame of the gene (Table 3). Additionally, we identified a frameshift mutation caused by the addition of an “A” at nucleotide 174 to \textit{FTT} \_\textit{0788c}/ \textit{kdsD} (984 bp) (Table 3). KdsD catalyzes the conversion of the pentose pathway intermediate R5P into A5P. A5P is a precursor of KDO, an integral part of the LPS which is an established virulence factor for \textit{F. tularensis} pathogenesis [63–68].

Construction of arabinose phosphate isomerase mutants

In order to explore the potential role of \textit{kdsD} in virulence, a mutant in \textit{kdsD} was constructed in a Schu S4 background. We used a modified TargetTron mutagenesis system and the Targettron plasmid pKEK1140 (Table 1) to disrupt the \textit{kdsD} gene at site 611|612s using retargeted mobile group II introns as described previously [70]. Confirmation of insertion of the intron was demonstrated by PCR analysis using the primers that flanked the insert region. For DNA from the Schu S4 strain, a PCR fragment of ~1.3 kb was observed. However for mutant strains that contained the intron insert, a PCR fragment increased by approximately 900 bp was observed (data not shown).

As \textit{F. novicida} is used as a surrogate for tularemia studies under BSL-2 conditions and to further verify the observations made with the \textit{kdsD} Schu S4 mutant, we also examined a mutant for the gene encoding arabinose phosphate isomerase in the U112 strain from a previously constructed transposition library [69]. The homologous gene in \textit{F. novicida} strain U112 is designated as \textit{kpsF} (\textit{FTN} \_\textit{1222}) [84] which we utilize here to distinguish between the two \textit{Francisella} species and mutant strains. The \textit{F. novicida} \textit{kpsF} gene is 969 bp in length and 99% identical to the \textit{F. tularensis} \textit{kdsD} gene at the amino acid level. Two independent transposon mutants were identified having insertions in the \textit{kpsF} gene; one was at nucleotide position 257 and the other was at position 394 [69]. However, we were unable to culture the latter mutant under various growth conditions, therefore all work described here was obtained using the former transposon mutant (BEI catalog # NR-6746).

MIC and \textit{in vitro} susceptibility testing of the \textit{kdsD}/ \textit{kpsF} mutants

To determine if the alteration of \textit{kdsD} in the CipR mutant had any role in antibiotic resistance, MIC values were obtained for the \textit{kdsD}::\textit{ltrB}_{L1} mutant and compared to the Schu S4 parent and CipR mutant (Table 4). As expected, no difference in resistance to ciprofloxacin was observed between Schu S4 parent and \textit{kdsD}::\textit{ltrB}_{L1} (MIC = <0.03 μg/ml). In contrast, high levels of resistance were still detected for the CipR mutant (64 μg/ml) (Table 4) as previously reported [26]. Likewise, no resistance to ciprofloxacin was observed between the \textit{F. novicida} U112 parent and the \textit{kpsF}::T20 mutant (Table 4).

| Table 4. MIC analysis. |
|------------------------|
| **Strain**              | **Ciprofloxacin (μg/ ml)** |
| \textit{F. tularensis} Schu S4 | <0.03 |
| \textit{F. tularensis} CipR | 64 |
| \textit{F. tularensis} \textit{kdsD}::\textit{ltrB}_{L1} | <0.03 |
| \textit{F. novicida} U112 | <0.03 |
| \textit{F. novicida} \textit{kpsF}::T20 | <0.03 |
| **QC Standards**        |                           |
| \textit{E. coli} ATCC 25922 | <0.03 |
| \textit{S. aureus} ATCC 29213 | 0.5 |
| \textit{P. aeruginosa} ATCC 27853 | 0.25 |

https://doi.org/10.1371/journal.pone.0174106.t004
In addition, we examined the Francisella mutant strains to determine if inactivation of kdsD or kpsF led to increased sensitivity to a panel of hydrophobic agents. As shown in Table 5, both the CipR and kdsD::ltrB11 mutant strains showed an increase in sensitivity to PMB, Tween 20, and SDS but not Triton-X 100. However, the only measurements that were significant were for Tween 20. When the kdsD::ltrB11 mutant was complemented with a functional kdsD gene on a plasmid, the levels of resistance to these compounds were restored to the parent levels. The F. novicida kpsF::T20 mutant was also examined; however, the only inhibitors which the kpsF::T20 mutant showed a significant increased sensitivity were Tween 20 and SDS (Table 5). This sensitivity was restored by complementation.

### Exogenous A5P restores growth of the kdsD::ltrB11 mutant in Chamberlain’s defined medium but not CipR

Additional characterization of the strains involved growth analysis in Chamberlain’s defined broth medium (CDM). As shown in Fig 1A, growth of the CipR and kdsD::ltrB11 mutant strains versus Schu S4 in CDM showed significant differences in maximum density (p < 0.0001), lag time (p < 0.0001), and maximum growth rate (p < 0.0001), respectively. For the kdsD::ltrB11 mutant strain, we demonstrated that this growth defect in CDM was due specifically to the inactivation of the gene because complementation with a functional kdsD gene in trans on a plasmid completely restored growth to those of Schu S4 (S1 Fig).

Similar results for growth in CDM with the F. novicida U112 parent and kpsF::T20 mutant strains were observed (Fig 1B). Overall, the mutant was more impaired for growth and significant differences between the two strains were observed for maximum density (p = 0.0001), lag time (p < 0.0001), and maximum growth rate (p < 0.0001). Complementation with a functional gene was again able to restore growth of the mutant to wild-type levels (S1 Fig).

As the KdsD/KpsF enzyme catalyzes the conversion of R5P into A5P, we hypothesized that these growth defects could be restored by adding A5P to the media. As shown in Fig 1, a significant increase in growth (as measured by maximum density, lag time, and growth rate; p < 0.0001) was observed for both F. tularensis kdsD::ltrB11 and F. novicida kpsF::T20 mutants when grown in the presence of 400 μM A5P versus growth without the additional A5P. In contrast, no difference was observed for the respective parent strains when grown with or without additional A5P (Fig 1). Interestingly, the Schu S4 CipR mutant did not show a significant

---

**Table 5. Susceptibilities of F. tularensis and F. novicida to hydrophobic agents.**

| Strain          | PMB ± SD | Tween 20 ± SD | Triton X ± SD | SDS ± SD |
|-----------------|----------|---------------|---------------|---------|
| Ft Schu S4      | 10.0 ± 0 | 18.1 ± 1.06   | 35.2 ± 3.01   | 34.1 ± 8.44 |
| Ft CipR         | 13.7±3.22| 32.5 ± 5.85* | 35.2 ± 4.27   | 36.97±6.51 |
| Ft kdsD::ltrB11 | 11.6 ± 0.2 | 24.9 ± 0.93* | 39.1 ± 0.98   | 52.20 ± 1.57 |
| Ft kdsD Comp    | 10.0 ± 0 | 18.7 ± 2.00   | 36.3 ± 1.12   | 32.0 ± 8.39 |
| Fn U112         | 19.2 ± 2.54| 10.0 ± 0     | 31.7 ± 2.51   | 23.0 ± 2.00 |
| Fn kpsF::T20    | 20 ± 0.89| 19.7 ± 1.96* | 29.6 ± 0.51   | 29.1 ± 0.56* |
| Fn kpsF Comp    | 20.2 ± 0.40| 10.0 ± 0    | 28.8 ± 6.75   | 24.8 ± 1.57 |

Sterile paper disks (10 mm in diameter) were saturated in polymyxin B at 10 mg/ml, Tween 20 at 5%, Triton X-100 at 5%, or SDS at 100 mg/ml, dried, and placed in triplicate onto separate agar plates. Sensitivity to each agent was assessed by measuring the diameter of the zone of growth inhibition around the disk. The results are in millimeters and the average of the multiple measurements of disks from three separate experiments. Those inhibitors which displayed significant differences (p < 0.05) with the mutants strain as compared to measurements with the respective parent strain are indicated by *.

1 ± SD (standard deviation)

https://doi.org/10.1371/journal.pone.0174106.t005
increase in growth with the addition of A5P, despite the fact that it also contains a frameshift mutation in \textit{kdsD}. Therefore, other mutations are presumably contributing to the growth defect in the CipR mutant.

The CipR and \textit{kdsD::ltrB} \textsubscript{L1} mutants are affected in O-antigen expression of the LPS and capsule but not lipid A

When performing western blot analysis with lysate material of equivalent bacterial CFU numbers extracted from wild-type Schu S4, CipR, or \textit{kdsD::ltrB} \textsubscript{L1} and monoclonal antibodies generated against LPS or the O-antigen capsule, the characteristic profiles of the wild-type strain were not observed in the CipR and \textit{kdsD::ltrB} \textsubscript{L1} mutant strains (Fig 2A). We note the extracts for the mutant strains did retain a slight band at approximately the 28 kDa marker. Likewise, when examining for the reactivity with the antibody to O-antigen capsule, some slight reactivity was still observed in the upper region (> 198 kDa) for the mutant strains. However, for both blots the level of reactivity was greatly diminished as compared to the parent strain. In contrast, no difference in GroEL levels was noted between the different strains. When the \textit{kdsD} mutant strain was complemented \textit{in trans} with a functional \textit{kdsD} gene, the LPS and O-antigen capsule profiles were completely restored to this strain (Fig 2A). Similar results were observed by western analysis with the \textit{kpP}::T20 transposon mutant strain and monoclonal antibody directed against the LPS of \textit{F. novicida} (Fig 2B), though some low level of reactivity with the LPS antibody was still detected. Again, the LPS profile could be completely restored via complementation (Fig 2B).
Negative ion mode MALDI-TOF mass spectrometry was used to further compare mutant and wild type LPS structures of *F. tularensis*. The MALDI process is capable of fragmenting the glycosidic bond that connects the core oligosaccharide to the lipid A moiety [85], allowing this structure to be elucidated from intact LPS preparations. We observed the prompt fragmentation of LPS and the resultant lipid A species using the data acquisition parameters used in these experiments (Fig 3). We observed the same lipid A structure and variants as reported by Kanistanon et al [29] where the species at m/z 1665.24 corresponds to the intact lipid A structure shown in Fig 3. The theoretical m/z for this molecule is 1665.25 [M-H]-. We determined experimental m/z values of 1665.24, 1665.24, 1665.24 and 1665.23 for LPS preparations from cultures of wild type Schu S4, CipR, *kdsD*:ltr*Bl*1, and *kdsD* complemented strains, respectively. The species at m/z 1504.2 (delta 161.0 Da) corresponds to the intact lipid A structure minus
one galactosamine unit. The minor peaks at m/z 1637.2 and 1476.2 correspond to shorter acyl chain lipid A variants (delta 28.0 Da) of the major peaks described above. We observed these same species in all four LPS preparations suggesting that the loss of the KDO structure in the two mutant strains (CipR and kdsD::ltrB_{L1}) does not impact the structure of lipid A. We did observe a lower intensity of lipid A within the kdsD::ltrB_{L1} mutant sample which likely resulted from decreased extraction efficiency of the sample material between the solvents during preparation of an LPS mutant. However, the main goal of this experiment was to simply demonstrate that the loss of KDO did not affect the lipid A structure in the remainder of the LPS molecule for the mutant strains which these results do conclusively show.

Interaction of Francisella strains with macrophage-like cells

The fate of the *F. tularensis* strains following uptake by J774A.1 cells was studied using a gentamicin protection assay to examine CFU recovery at 4 h and 24 h post-challenge. These data are depicted in Figs 4A, 4B and 5A as “percent CFU increase” and show the differences in CFU recovery between these time points for the various *F. tularensis* and *F. novicida* strains. Little difference in the initial recovery of CFUs between Schu S4 and CipR or kdsD::ltrB_{L1} strains was observed at the 4 hour time point (data not shown), suggesting the initial uptake of the bacteria was not affected. However, after a 24 h incubation period, the recovered number of CFUs had increased by several logs for J774A.1 cells infected with Schu S4. In contrast, the number of CFUs recovered from J774A.1 cells infected with CipR (Fig 4A) or kdsD::ltrB_{L1} (Fig 4B) mutant strains had decreased significantly as compared to CFU counts with the wild-type strain. To demonstrate if this difference was due specifically to the inactivation of *kdsD*,
J774A.1 cells were infected with the \textit{kdsD} complemented strain. As shown in Fig 4B, a several log increase of CFUs was observed for macrophages infected with the complemented strain after the 24 h post-challenge time point.

During these studies, a disruption in the confluence of the macrophage monolayers was also noted after the 24 h incubation with either CipR or \textit{kdsD::ltrB\textsubscript{L1}} \textit{F. tularensis} mutant strains but not with the parent Schu S4 or \textit{kdsD} complemented strains (Fig 4C). Previous studies with other \textit{F. tularensis} mutants containing LPS defects had shown similar induction of macrophage death [33, 86, 87]. Therefore, the loss of CFU recovery with the \textit{F. tularensis} mutants from our current study could be due to either a defect in the ability of the mutants to replicate intracellularly or the loss of the host cells and therefore the intracellular replicative niche of the bacteria.

Similar results were observed when examining the recovery of CFUs with the \textit{F. novicida kpsF::T20} mutant from infected J774A.1 cells. As shown in Fig 5A, a several log CFU increase was observed with the U112 wild-type strain 24 h-post challenge. In contrast, no increase in the CFUs was observed with the \textit{kpsF::T20} mutant and significantly differed ($p = 0.0034$) from J774A.1 cells infected with the wild-type strain. However, when a functional gene was supplied to the mutant via complementation, CFU recovery was restored to the mutant strain. The fate of the macrophages infected with the \textit{F. novicida} LPS mutant was also examined. We demonstrated that cell death was occurring at 18 h post infection as detected by Caspase 3/7 activity (Fig 5B & 5C), and the increase in Caspase 3/7 activity can be seen as early as 12 h post infection (data not shown). The J774A.1 cells infected with the \textit{kpsF::T20} mutant strain were found to be undergoing host cell death at a much higher level than observed with cells infected with the U112 strain or uninfected macrophages. However, if the mutant was complemented, little cell death was observed (Fig 5B & 5C).
The CipR and \textit{kdsD::ltrB$_{L1}$} mutants of \textit{F. tularensis} were highly attenuated in mice

To determine if the CipR and \textit{kdsD::ltrB$_{L1}$} mutant strains were still virulent in mice, various models of tularemia challenges were tested. The murine LD$_{50}$ measurements for the wild-type strain by intranasal and intradermal challenges were both determined to be 1–2 CFU (Fig 6; Table 6). In contrast, the LD$_{50}$ values for the CipR mutant by these same challenge routes were greatly increased: 14,000 and $>$49,000 CFU, respectively (Fig 6; Table 6). Likewise, complete attenuation was observed for mice challenged by the intranasal and intradermal routes for all challenge doses with the \textit{kdsD::ltrB$_{L1}$} mutant. LD$_{50}$ measurements for the \textit{kdsD::ltrB$_{L1}$} mutant were $>$82,000 and $>$36,000 CFU, respectively (Fig 6; Table 6). To demonstrate this severe attenuation of the \textit{kdsD} gene, mice were intranasally challenged with the complemented mutant (Fig 6; Table 6). Almost complete restoration of virulence was observed when mice were...
challenged by the intranasal route with a complemented \textit{kdsD} strain, with the LD$_{50}$ determined to be $<10$ CFU (Table 6).

Fig 6. The CipR and \textit{kdsD::ltrB$_L$} mutant strains of \textit{F. tularensis} were attenuated in BALB/c mice by intranasal and intradermal challenge. Groups of BALB/c mice (n = 10) were challenged and survival monitored following infection by intranasal or intradermal injections using the wild-type Schu S4 strain, CipR mutant, \textit{kdsD::ltrB$_L$} mutant, and the complemented \textit{kdsD} mutant strain, as indicated. The calculated LD$_{50}$ values from these experiments are included in Table 6.

https://doi.org/10.1371/journal.pone.0174106.g006
The recovery and dissemination of the CipR and kdsD::ltrB L1 mutants were hindered after intranasal challenge

To determine the fate of the CipR and kdsD::ltrB L1 F. tularensis mutants after intranasal challenge, groups of mice were separately exposed to wild-type Schu S4 (131 CFU), CipR (1,750 CFU), or kdsD::ltrB L1 (6,000 CFU). At set time points after challenge, mice from each group were euthanized for determining either bacterial burden from lungs and spleens (Fig 7) or assessing histopathological changes (Fig 8).

For mice receiving the wild-type Schu S4, the number of bacteria recovered from the lungs and spleens increased exponentially after Day 1 (Fig 7). By Day 5, all mice were moribund and one had succumbed to infection. For the remaining mice, lungs and spleens contained approximately $10^9$ CFU/g (Fig 7). In contrast, the number of CFUs recovered from the organs of mice infected with the CipR or the kdsD::ltrB L1 mutant strains were greatly reduced as compared to mice challenged with the Schu S4 parent strain. For the lungs over the first 7 days of testing, little change in the recovered CFUs was observed as compared to CFUs at 6 hours post-challenge. At the end of the study on Day 28, the remaining challenged mice were tested for the presence of bacteria within their organs. On Day 26, two of the CipR challenged mice had succumbed to infection. The lungs from the remaining CipR challenged mice were still shown to contain some CFUs but still at a relatively low level. All of the kdsD::ltrB L1 challenged mice survived until Day 28, and the lungs of these mice were found to be free of F. tularensis (Fig 7).

Overall very few of the spleens of the CipR or kdsD::ltrB L1 mutant challenged mice had any CFUs recovered over the first 2 days. Over the remaining week of testing, the number of spleens shown to contain CFUs was inconsistent, with many being negative for the presence of F. tularensis. At the end of the study, one of the spleens from the CipR challenged mice had a low level of CFUs recovered. However, none of the spleens for the kdsD::ltrB L1 challenged mice had bacteria present.

Histopathological analysis of intranasal challenged mice

Along with testing for the presence and trafficking of F. tularensis from the lungs, additional mice (n = 3) were processed to compare histopathological differences in disease progression following intranasal challenge with the wild type Schu S4 or the two mutant strains (Fig 8). All pathology images in Fig 8 are comparing the challenged mice at Day 5. It is at this time point that all wild-type challenged mice become moribund versus complete survival for the mice challenged with the CipR or kdsD mutant strains. Additional pathology images throughout the time course of this study are provided as supplementary data (S2–S4 Figs) as indicated below.
When examining organs from mice on Day 1 post-challenge with Schu S4, the mice did not have any lesions suggestive of tularemia. The lesions in these animals were limited to non-specific hyperplasia of lymphoid tissue in various lymph nodes and in the white pulp of the spleen (S2 Fig). However, by Day 3 post-exposure, mice demonstrated lesions consistent with tularemia infection [21, 23, 88]. These lesions consisted of small multifocal random areas of necrosis and neutrophilic inflammation in the sinusoids of the liver, red and white pulp of the spleen, cortex and medulla of the lymph nodes, and interstitium of the lung (S3 Fig). For mice on Day
5 post-exposure, lesions consisted of random foci of lytic necrosis and neutrophilic inflammation in the liver, spleen, lungs, and lymph nodes (Fig 8). Additionally, there were numerous intralesional large colonies of coccobacilli, morphology consistent with \textit{F. tularensis}.

When examining mice receiving the CipR strain, no lesions were observed on Day 1 (S2 Fig). By Day 2 post-exposure, 2/3 mice had minimal multiple foci of necrosis and neutrophilic inflammation in the liver, spleen, lungs, and lymph nodes (Fig 8). Additionally, there were numerous intralesional large colonies of coccobacilli, morphology consistent with \textit{F. tularensis}.

![Fig 8. Pathology of mice challenged intranasally with \textit{F. tularensis} 5 days post-challenge. Mice were challenged intranasally with Schu S4 WT (131 CFU), CipR mutant (1,750 CFU), or \textit{kdsD::ltrB}_{L1} (6,000 CFU). Also included as a control for these studies were mice receiving PBS alone by intranasal administration. The strains used for challenge and HE stained organ (lung, spleen, and liver) are as indicated. All samples shown are at 5 days post-challenge when the Schu S4 challenged mice were moribund; in contrast, the mutant challenged mice displayed no clinical signs of infection at this time point. Schu S4 WT, Lung (4x)–multifocal areas of inflammation and necrosis (*); arrow indicates the inset area. Inset (40x)–necrosis admixed with inflammatory cells. Spleen (4x)–coalescing areas of necrosis (*) affecting red pulp and white pulp; arrow indicates the inset area. Inset (40x)–necrosis admixed with inflammatory cells. Liver (4x)–Single focus of necrosis (*); arrow indicates the inset area. Insert (40x)–necrosis admixed with few inflammatory cells. CipR mutant, Lung (4x)–diffuse coalescing necrotic areas. Inset (40x)–necrosis admixed with inflammatory cells. Spleen (4x)–normal. Liver (4x)–normal. \textit{kdsD::ltrB}_{L1}, Lung (4x)–few foci of necrosis (*); arrow indicates the inset area. Inset (40x)–necrosis admixed with inflammatory cells extends to the surface of the lung. Spleen (4x)–normal. Liver (4x)–normal.](https://doi.org/10.1371/journal.pone.0174106.g008)
inflammation in the lung (pneumonia). The areas of necrosis and inflammation in the lung appeared to be random and associated with small airways (alveoli). Similar pneumonia is noted in all day 3 mice (S3 Fig). In all Day 4 mice, there is similar minimal to mild pneumonia with extension to the surface of the lungs (pleura), and admixed with the necrosis and neutrophils are discernible histiocytes/macrophages. In all Day 5 post-exposure mice, there was mild to moderate pneumonia with extension to the surface of the lungs (pleura) and admixed with the necrosis and neutrophils are discernible histiocytes/macrophages (Fig 8). The pneumonia in the Day 5 mice involved 10–25% of the lung parenchyma versus less than 10% of the lung parenchyma for Day 2 through Day 4 mice. In 1/3 mice from the Day 5 post-challenge, there was minimal focal necrosis with neutrophilic inflammation in the liver (Fig 8). At Day 28, there were diffuse mild to moderate to marked lymphoplasmacytic and histiocytic pleuropneumonia with some neutrophils associated with the aforementioned inflammatory infiltrate in the lung parenchyma and within bronchiolar lumina. There was minimal lymphoid hyperplasia in the white pulp of the spleen in all mice. Similar lymphoid hyperplasia was observed in 2/5 Day 28 mice in the tracheobronchial lymph node (S4 Fig). It should be noted that all of the F. tularensis challenged mice were compared to mice receiving only PBS intranasally for comparison, and no lesions were noted in any of the organs (Fig 8).

Overall, similar lesions were observed for mice challenged intranasally with the kdsD::ltrB<sub>L1</sub> mutant as described above for the CipR mutant. Mice sacrificed on Day 1 demonstrated multiple and random foci of necrosis and neutrophilic inflammation in the lung (pneumonia) (S2 Fig). In all mice in this group, the severity was judged to be only minimal affecting less than 5% of the lung. All Day 2 mice had similar minimal pneumonia. By Day 3 post-infection, there was similar pneumonia, mild in two mice and moderate in one mouse. The necrosis and inflammation in the Day 3 mice extended to the pleural surface in 2/3 mice and affected pulmonary vessels in all three. The pneumonia was still characterized by necrosis and neutrophilic infiltrates, but in two mice, histiocytes/macrophages were also observed (S3 Fig). Within the Day 4 group, there was minimal to moderate pneumonia that extended to the pleural surface in all three mice. The pneumonia was characterized by necrosis and neutrophilic, histiocytic, and lymphoplasmacytic infiltrates. Additionally on Day 4, there are random areas of hepatocyte degeneration and necrosis with neutrophilic and histiocytic inflammation. In all Day 5 mice, there was mild multifocal neutrophilic, histiocytic, and lymphoplasmacytic pneumonia and mild necrosis with neutrophils and histiocytes in the liver (Fig 8). On Day 28, 2/3 mice had mild multifocal lymphoplasmacytic and histiocytic inflammation in the lung and pleura with no necrosis (S4 Fig).

The CipR and kdsD::ltrB<sub>L1</sub> F. tularensis mutants are attenuated when mice are exposed to aerosolized bacteria

Aerosol exposure of F. tularensis is the greatest threat from a biodefense perspective. Accordingly, the ability of the CipR and kdsD::ltrB<sub>L1</sub> mutant strains to be aerosolized and cause infection in mice was also explored. Since both mutant strains were highly attenuated via the intranasal route of challenge, mice were exposed to a single high dose of F. tularensis via small particle aerosol. All mice survived exposure to the CipR mutant (the equivalent of 43 wild-type LD<sub>50</sub>) or kdsD::ltrB<sub>L1</sub> mutant (the equivalent of 100 wild-type LD<sub>50</sub>) during the entire course of the study (21 days) (Fig 9). In contrast, all mice receiving aerosolized Schu S4 (33 LD<sub>50</sub>) succumbed to infection by Day 5 (Fig 9). The LD<sub>50</sub> for BALB/c mice exposed to aerosolized Schu S4 bacteria is approximately 300 CFU [21, 22].

To determine what, if any, pathological changes occurred in mice surviving aerosol challenge with the mutant strains as compared to mice exposed to the wild-type Schu S4 strain, mice were
A ciprofloxacin resistant strain of *F. tularensis* is highly attenuated

For mice challenged with the wild-type Schu S4 strain, the microscopic lesions were typical of *F. tularensis* and resulted in the death of these mice. The most significant lesions were noted in the spleen and lung. The lesions in the spleens were characterized by necrosis with neutrophilic inflammation and fibrin (Fig 10). In the lungs, there was necrosis and neutrophilic inflammation (necrosuppurative) of the parenchyma and pleura (pleuropneumonia). There was also mild to moderate inflammation of lung vessels (vasculitis) characterized by necrosis and neutrophilic inflammation within vessel walls, often with fibrin thrombi (Fig 10). The livers of the moribund mice contained multiple minimal to mild areas of necrosis with neutrophilic inflammation within vessel walls, often with fibrin thrombi (Fig 10). Likewise for mice surviving aerosol challenge with the *kdsD::ltrB*_L1 mutant, a very similar course of disease for the mice was observed as described above for the CipR mutant strain. The one slight difference was that the inflammation in the lungs of the mice exposed to the CipR mutant may be slightly more severe based upon subjective assessment of the amount of lung parenchyma affected. Overall for the lungs of the *kdsD::ltrB*_L1 exposed mice, there was minimal to mild lymphoplasmacytic and histiocytic inflammation with few scattered neutrophils, often associated with bronchioles in the lung (Fig 10). The inflammation is indicative of a chronic resolving process from aerosol challenge.
exposure to the \( kdsD::ltrB_{L1} \) mutant. Finally, no other lesions or pathologic changes were noted in the liver or spleens of the mice surviving aerosol challenge with CipR or \( kdsD::ltrB_{L1} \) mutant in contrast to the severe pathologic changes observed with mice succumbing to infection with the wild-type Schu S4 strain (Fig 10).

**Fig 10. Pathology of mice challenged by small particle aerosol with \( F. tularensis \).** The strains used for aerosol challenge (Schu S4 WT, CipR, and \( kdsD::ltrB_{L1} \)) and the HE stained organ (lung, spleen, and liver) are as indicated. The mice challenged with Schu S4 were collected at Day 5 when all mice had succumbed to infection. The mice challenged with the CipR or \( kdsD::ltrB_{L1} \) mutant survived till the end of the study (Day 21) and displayed no clinical signs of infection. Schu S4 WT: Lung (4x)—multifocal areas of inflammation and necrosis (*); arrow indicates the inset area. Inset (40x)—necrosis admixed with inflammatory cells. Spleen (4x)—diffuse coalescing areas of necrosis (*) affecting red pulp and white pulp. Inset (40x)—necrosis (*) admixed with inflammatory cells; arrow indicates the inset area. Liver (10x)—Single focus of necrosis (*); arrow indicates the inset area. Insert (40x)—necrosis with few inflammatory cells. CipR: Lung (4x)—Diffuse coalescing areas of necrosis (*) with inflammatory cells that extend to the surface of the lung. Spleen (4x)—normal. Liver (10x)—normal. \( kdsD::ltrB_{L1} \): Lung (4x)—foci of necrosis (*) centered on a large airway. Spleen (4x)—normal. Liver (10x)—normal.

https://doi.org/10.1371/journal.pone.0174106.g010

The \( kpsF::T20 \) mutant of \( F. novicida \) is highly attenuated for mice

As \( F. novicida \) is frequently used as a surrogate for tularemia studies, we wished to demonstrate if the \( F. novicida kpsF::T20 \) mutant was also attenuated in a murine model of inhalational tularemia to further corroborate the studies performed with the \( kdsD \) mutant in \( F. tularensis \) described above. As shown in Fig 11 and Table 6, we challenged groups of mice intranasally with either the \( F. novicida \) U112 parent strain or the \( kpsF::T20 \) mutant. All mice receiving the parent strain succumbed to infection, and the \( LD_{50} \) was >24 CFU (Fig 11 & Table 6).
However, mice receiving the kpsF::T20 mutant were able to survive challenge except for those receiving the highest mutant doses (Fig 11). The LD$_{50}$ for the kpsF::T20 mutant was calculated to be 25,119 CFU (Table 6). The attenuation observed for the kpsF::T20 mutant nearly restored when a functional gene was supplied in trans on a plasmid (Fig 11). The LD$_{50}$ for the complemented strain was calculated to be 32 CFU (Table 6).

Fig 11. The kpsF::T20 mutant of F. novicida is highly attenuated by intranasal challenge in BALB/c mice. Groups of BALB/c mice were challenged intranasally with the parent U112 strain of F. novicida, the kpsF::T20 mutant, or the complemented kpsF mutant. The calculated LD$_{50}$ values from these experiments are included in Table 6.

https://doi.org/10.1371/journal.pone.0174106.g011
Discussion

Bacterial resistance to antibiotics is a serious threat to the public health and the biodefense communities. The goal of this study was to further characterize a ciprofloxacin resistant strain of *F. tularensis* [26]. Our intent was to better understand the bacterial pathogenesis and threat a resistant strain might pose whether it arise naturally or made intentionally. The major findings of our work are as follows. 1) The CipR mutant was severely hampered in its ability to cause infection in all tested murine models of tularemia. 2) In addition to the previously identified changes to *gyrA* and *parE* [26], the genome of the CipR mutant contained additional genetic alterations, including in *kdsD*, the mutated gene that likely is responsible for the attenuation in the CipR mutant strain. 3) Both *F. tularensis* Schu S4 *kdsD* and *F. novicida* U112 *kpsF* mutations led to LPS alterations and attenuation in mice.

In addition to being highly resistant to ciprofloxacin, the CipR mutant displayed other phenotypes: *in vitro* growth defects, increased sensitivity to hydrophobic agents, LPS profile alterations, increased induction of mammalian cell death, and high attenuation in multiple models of murine tularemia. Many of these additional characteristics, albeit not all, are likely due to the frameshift in *kdsD* which occurred during the selection process but was not associated with ciprofloxacin resistance. Mutations specifically to the *kdsD*/*kpsF* gene replicated many of the characterizations observed with the CipR mutant. We focused on the mutation of *kdsD* in the CipR mutant to better understand the phenotype of this strain since it was the only gene, outside of *parE*, exhibiting a frameshift mutation which presumably would result in a higher impact effect. We hypothesized that KdsD plays an important role in virulence because it synthesizes an LPS precursor and LPS is an established virulence factor for *F. tularensis* [63–68].

Whereas *kdsD* and *parE* are frameshift mutations, the other altered genes on the chromosome of the CipR mutant led to amino acid substitutions within the effected protein (Table 3). This does not discount the possibility that these other mutations may contribute in part to the loss of virulence or other phenotypes observed for the CipR strain. Some of these alterations occurred to genes encoding for other known *Francisella* virulence factors, such as *Ftt_0807*/capA [89, 90] and *fupA* [91, 92]. The role, if any, in *Francisella* pathogenesis for the other proteins remains to be determined. The FabH and FabF proteins are both enzymes involved in type II fatty acid biosynthesis system which are required for synthesis of essential lipoproteins, phospholipids, and LPS [93, 94]. Presently, little else is known about FtaG (*FTT_1573c*), an outer membrane surface antigen [95]. Likewise, *Ftt0_676* encodes for an ion transporter which has been shown to be downregulated when *F. tularensis* is present within macrophages [96].

In addition, as shown in Fig 1A, the growth defects of the *kdsD* mutant in Schu S4 and *kpsF::T20* mutant in U112 were restored to the respective wild-type levels when providing exogenous A5P, the end product of the D-arabinose 5-phosphate isomerase activity. This growth defect was not able to be restored to the CipR strain when providing A5P, demonstrating additional defects to this mutant.

Many of the observed characteristics for CipR mutant were similar to the Schu S4 *kdsD::ltrB* mutant, such as a defect in the LPS profile. This would not be surprising as the *kdsD* gene encodes for the enzyme catalyzing the first step for KDO biosynthesis. As the CipR and *kdsD::ltrB* mutants would not be able to form KDO, the link between lipid A and the polysaccharide core and O-antigen would be affected, therefore the resulting mutant strains would be severely disrupted for these structures. Although, our study is the first to examine a *kdsD* mutant of *F. tularensis*, a recent report describes a transposon mutant in *kdsB* (*FTT_1478c*) which encodes for cytidine 5’-monophospho-KDO synthase. The *kdsB* mutant also did not react with antibodies generated against LPS or the O-antigen capsule, but virulence studies were not reported for this mutant [86]. The results for a defect of the capsule on both the CipR
and kdsD::ltrB11 mutants provide further evidence that a full-length LPS serves a scaffold for formation of this structure as previously suggested [66]. However, a previous study with a lpxL (encoding for a lipid A acyltransferase) mutant which expresses only a portion of the LPS core still expressed a capsular antigen [63]. The exact reason for this discrepancy remains to be determined. In addition to defects in the LPS profile, the CipR and kdsD::ltrB11 mutants also recapitulate characteristics similar to phenotypes described for other F. tularensis LPS and O-antigen mutants: early induction of death to macrophages [86, 87] and attenuation in murine models of tularemia [66, 97, 98].

In our current study, the pathology noted with mice challenged intranasally or by small particle aerosol with the wild-type Schu S4 are in general agreement with other published studies [21, 88]. For pneumonic tularemia challenges by both routes with Schu S4, the lungs of infected mice showed lesions characterized by necrosis and neutrophilic inflammation of the parenchyma and pleura. The lesions in the spleens were additionally characterized by multifocal and random necrosis. The BALB/c mice were extremely sensitive to challenge by the intranasal route with Schu S4 as the LD$_{50}$ was determined to be 1–2 CFUs. In contrast, mice that were intranasally challenged with the CipR strain or the kdsD::ltrB11 mutant were highly resistant (Table 6). However, when the intranasal challenge doses for the CipR mutant reached the range of ~10,000 CFUs, 3/10 mice did succumb by Day 16. Nevertheless, this is a much later time point than observed with mice challenged with wild-type Schu S4 which succumbed to infection by Day 5 when exposed to 300 CFU. In contrast, no mice challenged with the kdsD::ltrB11 mutant succumbed to infection or showed any outward clinical signs, even at the highest challenge dose (82,000 CFU).

Thus, the kdsD::ltrB11 mutant does appear to be slightly more affected for virulence by pneumonic challenge models even though both the CipR and kdsD mutant strains are highly attenuated. This was also reflected in the pathology results for the aerosol challenged mice where a slight increase in lung necrosis and inflammation was noted in the lungs of the CipR mutant challenged mice as compared to the kdsD::ltrB11 mutant challenged mice. In addition, the mice challenged with the kdsD::ltrB11 mutant were estimated to have received over twice the dose as compared to the CipR mutant challenged mice. The exact reasoning for this slight difference in the level of attenuation between CipR and kdsD::ltrB11 mutants remains to be determined and was unexpected as the CipR strain contains additional genetic changes. Potential reasons for this difference could be that the CipR mutant challenged mice lead to a hyperinduction of the immune response leading to increased damage since these bacteria remain longer in the lungs (Fig 7).

Other LPS (waaY and waaL) mutants in a Schu S4 background showed similar high levels of attenuation in BALB/c mice following intranasal challenge as determined by LD$_{50}$ measurements (1.3x10$^6$ and 3x10$^3$, respectively) [66]. However, we noted several differences in the infection of BALB/c mice between the mutant strains. The Schu S4 waaY and waaL mutant strains examined by Rasmussen et al [66] both appeared to have induced a higher level of lung necrosis when mice were challenged with 10$^6$ CFU of either mutant strain. In contrast, the kdsD::ltrB11 mutant in our study showed less severe pneumonia early on following intranasal challenge compared to infection with the parent Schu S4 strain albeit, our challenge dose was with the kdsD::ltrB11 mutant was several logs lower (6x10$^3$ CFU). The waaY and waaL Schu S4 mutants were also able to disseminate from the lungs and replicate within the mouse organs examined [66]. In our study, the kdsD::ltrB11 mutant was recovered poorly from the spleens following intranasal challenge, and CFUs recovered from the lungs did not increase over the time course examined.

Two possibilities might explain the differences between the studies. Firstly, the waaY and waaL F. tularensis mutants expressed a truncated LPS structure and retained a partial O-
antigen structure [66]. In contrast, the \textit{kdsD::ltrB\textsubscript{L1}} mutant is unable to synthesize KDO; therefore expression of a complete core or O-antigen structure is greatly hindered (Fig 2). The \textit{kdsD::ltrB\textsubscript{L1}} mutant with a more dramatic LPS deficiency is likely more attenuated. Secondly, the doses used for the mouse challenges with the mutant strains in the two studies differed \((10^6 \text{ CFUs for } \textit{waaY} \text{ and } \textit{waaL} \text{ versus } 10^3 \text{ CFUs for } \textit{kdsD::ltrB\textsubscript{L1}})\) therefore making a direct comparison in histopathology difficult.

Other LPS mutants of \textit{F. tularensis} have demonstrated the potential to provide a protective response against parent strain challenges [66, 68, 97, 99–101]. Future vaccination studies with the Schu S4 \textit{kdsD::ltrB\textsubscript{L1}} mutant may be warranted to determine if some level of protection could be provided against challenge with fully virulent \textit{F. tularensis} strain. Although, as detailed above, the dissemination and recovery of the \textit{kdsD::ltrB\textsubscript{L1}} mutant post-challenge was rather limited (Fig 7) as compared to the dissemination of other Schu S4 LPS mutant strains which allowed protection [66]. Therefore, efficacy of the \textit{kdsD::ltrB\textsubscript{L1}} mutant as a live vaccine could be limited.

However, a more promising avenue to explore is the potential of \(\text{D-}\text{arabinose 5-phosphate isomerase (KdsD)}\) to serve as a therapeutic target as previously proposed [102, 103]. This enzyme would be an attractive target for novel therapeutics against gram-negative bacteria as KDO is necessary for LPS synthesis and bacterial virulence. In addition, A5P would not be present within mammalian tissues to provide an exogenous source to infecting gram-negative bacteria. Furthermore, structural analyses studies have identified putative active sites for catalysis [104, 105], opening the possibility for the screening of small molecule inhibitors for drug design. Such novel targets and mechanisms of action are currently needed to combat antimicrobial resistance.

**Supporting information**

**S1 Fig. Complementation of growth.** \textit{F. tularensis} (A) or \textit{F. novicida} (B) strains were grown in Chamberlain’s defined medium (CDM) at 37\(^\circ\)C. Growth was monitored by optical density. OD measurements were based upon quadruplicate samples and bars represent standard error of the mean. The \textit{F. tularensis kdsD::ltrB\textsubscript{L1}} and \textit{F. novicida kpsF::T20} mutants were severely altered for growth in CDM. However, when a functional \textit{kdsD} gene was supplied in trans on a plasmid to the mutants, growth was restored to the complemented strains.

(TIF)

**S2 Fig. Pathology of mice challenged intranasally with \textit{F. tularensis} 1 day post-challenge.** Mice were challenged intranasally with Schu S4 WT, CipR mutant, or \textit{kdsD::ltrB\textsubscript{L1}}. The strains used for challenge and hematoxylin and eosin (HE) stained organ (lung, spleen, and liver) are as indicated.

(TIF)

**S3 Fig. Pathology of mice challenged intranasally with \textit{F. tularensis} 3 days post-challenge.**

(TIF)

**S4 Fig. Pathology of mice challenged intranasally with \textit{F. tularensis} 28 day post-challenge.** Only CipR and \textit{kdsD::ltrB\textsubscript{L1}} mutant challenged mice survived to the end of the study.

(TIF)

**Acknowledgments**

The authors thank David Fetterer for performing the statistical analysis; Kiley Duncan, Kyle Fitts, and Joshua Roan with assistance with the macrophage assays; Steven Tobery for assisting
with the intradermal challenges; and Lorraine Farinick with preparation of the figures. The Francisella targeting vector pKEK1140 was generously provided by Karl Klose, University of Texas at San Antonio, San Antonio, TX. The shuttle vector plasmid pMP831 was generously provided by Martin S. Pavelka Jr, University of Rochester Medical Center, Rochester, NY. The monoclonal antibody 11B7 was generously provided by Michael Apicella, University of Iowa, Iowa City, IA.

Fabrice Biot performed this work at USAMRIID as part of the Engineer and Scientist Exchange Program.

Opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by the U.S. Army.

Author Contributions

Conceptualization: JC JEN PLW TMK JAB.

Data curation: JTL GK SL.

Formal analysis: JTL JEN SD GK SL.

Funding acquisition: GP PLW.

Investigation: TC JC RGT JTL JEN JLR FVB SD LM SH SM GK SL CKC TMK JAB.

Methodology: JC TMK JAB.

Project administration: TC JTL SD GP NJV PLW TMK JAB.

Resources: JEN GP.

Supervision: TC JTL SD GP NJV PLW TMK JAB.

Writing – original draft: TC JC JTL JEN JLR SD.

Writing – review & editing: TC JC JTL JEN JLR SD CKC.

References

1. McCaffrey RL, Allen LA. Francisella tularensis LVS evades killing by human neutrophils via inhibition of the respiratory burst and phagosome escape. Journal of leukocyte biology. 2006; 80(6):1224–30. PubMed Central PMCID: PMC1828114. https://doi.org/10.1189/jlb.0406287 PMID: 16908516

2. Hall JD, Craven RR, Fuller JR, Pickles RJ, Kawula TH. Francisella tularensis replicates within alveolar type II epithelial cells in vitro and in vivo following inhalation. Infect Immun. 2007; 75(2):1034–9. PubMed Central PMCID: PMC1828526. https://doi.org/10.1128/IAI.01254-06 PMID: 17088343

3. Clemens DL, Horwitz MA. Uptake and intracellular fate of Francisella tularensis in human macrophages. Ann N Y Acad Sci. 2007; 1105:160–86. https://doi.org/10.1196/annals.1409.001 PMID: 17435118

4. Lindemann SR, McLendon MK, Apicella MA, Jones BD. An in vitro model system used to study adherence and invasion of Francisella tularensis live vaccine strain in nonphagocytic cells. Infect Immun. 2007; 75(6):3178–82. Epub 2007/03/07. https://doi.org/10.1128/IAI.01811-06 PMID: 17339345

5. Craven RR, Hall JD, Fuller JR, Taft-Benz S, Kawula TH. Francisella tularensis invasion of lung epithelial cells. Infect Immun. 2008; 76(7):2833–42. PubMed Central PMCID: PMC2446690. https://doi.org/10.1128/IAI.00043-08 PMID: 18426871

6. Anthony LD, Burke RD, Nano FE. Growth of Francisella spp. in rodent macrophages. Infect Immun. 1991; 59(9):3291–6. PubMed PMID: 1879943; PubMed Central PMCID: PMC258167. PMID: 1879943

7. Bolger CE, Forestal CA, Italo JK, Benach JL, Furie MB. The live vaccine strain of Francisella tularensis replicates in human and murine macrophages but induces only the human cells to secrete proinflammatory cytokines. Journal of leukocyte biology. 2005; 77(6):893–7. https://doi.org/10.1189/jlb.1104637 PMID: 15758077
8. Bosio CM, Dow SW. *Francisella tularensis* induces aberrant activation of pulmonary dendritic cells. Journal of Immunology. 2005; 175(10):6792–801.

9. Nutter JE, Myrvik QN. *In vitro* interactions between rabbit alveolar macrophages and *Pasteurella tularensis*. Journal of Bacteriology. 1966; 92(3):645–51. PubMed Central PMCID: PMC276304. PMID: 5922539

10. Roberts LM, Tuladhar S, Steele SP, Rieber KJ, Chen CJ, Cumming RI, et al. Identification of early interactions between *Francisella* and the host. Infect Immun. 2014; 82(6):2504–10. PubMed Central PMCID: PMC4019147. https://doi.org/10.1128/IAI.01654-13 PMID: 24686053

11. Bar-Haim E, Gat O, Markel G, Cohen H, Shafferman A, Velan B. Interrelationship between dendritic cell trafficking and *Francisella tularensis* dissemination following airway infection. PLoS pathogens. 2008; 4(11):e1000211. PubMed Central PMCID: PMC2582141. https://doi.org/10.1371/journal.ppat.1000211 PMID: 1902342

12. Santic M, Molmeret M, Klose KE, Abu Kwaik Y. *Francisella tularensis* travels a novel, twisted road within macrophages. Trends Microbiol. 2006; 14(1):37–44. Epub 2005/12/17. https://doi.org/10.1016/j.tim.2005.11.006 PMID: 16356719

13. Ozanic M, Marecic V, Abu Kwaik Y, Santic M. The Divergent Intracellular Lifestyle of *Francisella tularensis* in Evolutionarily Distinct Host Cells. PLoS pathogens. 2015; 11(12):e1005208. PubMed Central PMCID: PMC4669081. https://doi.org/10.1371/journal.ppat.1005208 PMID: 26633893

14. Jellison WL. Tularemia: geographical distribution of deerfly fever and the biting fly, *Chrysops discalis* Williston. Public health reports. 1950; 65(4):1321–9. PMID: 14776201

15. Ellis J, Oyston PC, Green M, Titball RW. Tularemia. Clinical microbiology reviews. 2002; 15(4):631–46. PubMed Central PMCID: PMC1266859. https://doi.org/10.1128/CMR.15.4.631-646.2002 PMID: 12364373

16. Markowitz LE, Hynes NA, de la Cruz P, Campos E, Barbaree JM, Plikaytis BD, et al. Tick-borne tularemia: an outbreak of lymphadenopathy in children. JAMA. 1985; 254(20):2922–5. PMID: 4057512

17. Goethert HK, Shani I, Telford SR 3rd. Genotypic diversity of *Francisella tularensis* infecting *Dermacentor variabilis* ticks on Martha’s Vineyard, Massachusetts. Journal of clinical microbiology. 2004; 42(11):4968–73. PubMed Central PMCID: PMC525218. https://doi.org/10.1128/JCM.42.11.4968-4973.2004 PMID: 15528681

18. Dennis DT, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, et al. *Francisella tularensis* as a biological weapon: medical and public health management. JAMA. 2001; 285(21):2763–73. Epub 2001/06/21. PMID: 11386933

19. Evans ME, Gregory DW, Schaffner W, McGee ZA. Tularemia: a 30-year experience with 88 cases. Medicine. 1985; 64(4):251–69. PMID: 3892222

20. Saslaw S, Eigelsbach HT, Prior JA, Wilson HE, Carhart S. Tularemia vaccine study. II. Respiratory challenge. Arch Intern Med. 1961; 107:702–14. Epub 1961/05/01. PMID: 13746667

21. Fritz DL, Englund MJ, Miller L, Waag DM. Mouse models of aerosol-acquired tularemia caused by *Francisella tularensis* types A and B. Comparative medicine. 2014; 64(5):341–50. PubMed Central PMCID: PMC4236782. PMID: 25402174

22. Heine HS, Chualala L, Riggins R, Cirz R, Cass R, Louie A, et al. Natural History of *Francisella tularensis* in Aerosol-Challenged BALB/c Mice. Antimicrobial agents and chemotherapy. 2016; 60(3):1834–40. https://doi.org/10.1128/AAC.02887-15 PMID: 26824958

23. Twenhafel NA, Alves DA, Purcell BK. Pathology of inhalational *Francisella tularensis* spp. *tularensis* SCHU S4 infection in African green monkeys (*Chlorocebus aethiops*). Veterinary pathology. 2009; 46(4):698–706. Epub 2009/03/12. https://doi.org/10.1354/vp.08-VP-0302-T-AM PMID: 19276059

24. Saslaw S, Eigelsbach HT, Wilson HE, Prior JA, Carhart S. Tularemia vaccine study. I. Intracutaneous challenge. Arch Intern Med. 1961; 107:689–701. Epub 1961/05/01. PMID: 13746668

25. Harris S. Japanese biological warfare research on humans: a case study of microbiology and ethics. Ann N Y Acad Sci. 1992; 666:21–52. PMID: 1297279

26. Loveless BM, Yermakova A, Christensen DR, Kondig JP, Heine HS 3rd, Wasieloski LP, et al. Identification of ciprofloxacin resistance by SimpleProbe, High Resolution Melt and Pyrosequencing nucleic acid analysis in biothreat agents: *Bacillus anthracis*, *Yersinia pestis* and *Francisella tularensis*. Molecular and cellular probes. 2010; 24(3):154–60. Epub 2010/01/27. https://doi.org/10.1016/j.mcp.2010.01.003 PMID: 20100564

27. Sutera V, Levert M, Burmeister WP, Schneider D, Maurin M. Evolution toward high-level fluoroquinolone resistance in *Francisella* species. The Journal of Antimicrobial Chemotherapy. 2014; 69(1):101–10. https://doi.org/10.1093/jac/dkt321 PMID: 23963236
28. Gestin B, Valade E, Thibault F, Schneider D, Maurin M. Phenotypic and genetic characterization of macrolide resistance in *Francisella* *tularensis* subsp. *holarctica* biovar I. The Journal of antimicrobial chemotherapy. 2010; 65(11):2359–67. https://doi.org/10.1093/jac/dkx315 PMID: 20837574

29. Kanistanton D, Hajjar AM, Pelletier MR, Gallagher LA, Kalhorn T, Shaffer SA, et al. A *Francisella* mutant in lipid A carbohydrate modification elicits protective immunity. *PLoS* pathogens. 2008; 4(2):e24. PubMed Central PMCID: PMC2233673. https://doi.org/10.1371/journal.ppat.0040024 PMID: 18266468

30. Sandstrom G, Sjostedt A, Johansson T, Kuoppa K, Williams JC. Immunogenicity and toxicity of lipopolysaccharide from *Francisella* *tularensis* LVS. FEMS microbiology immunology. 1992; 5(4):201–10. PMID: 1419118

31. Wang X, Ribeiro AA, Guan Z, Abraham SN, Raetz CR. Attenuated virulence of a *Francisella* mutant lacking the lipid A 4'-phosphatase. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104(10):4136–41. PubMed Central PMCID: PMC1820721. https://doi.org/10.1073/pnas.0611606104 PMID: 17360489

32. Wang X, Ribeiro AA, Guan Z, McGrath SC, Cotter RJ, Raetz CR. Structure and biosynthesis of free lipid A molecules that replace lipopolysaccharide in *Francisella* *tularensis* subsp. *novicida*. Biochemistry. 2006; 45(48):14427–40. PubMed Central PMCID: PMC2569856. https://doi.org/10.1021/bi061767s PMID: 17128982

33. Weiss DS, Brotcke A, Henry T, Margolis JJ, Chan K, Monack DM. *In vivo* negative selection screen identifies genes required for *Francisella* virulence. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104(14):6037–42. PubMed Central PMCID: PMC1832217. https://doi.org/10.1073/pnas.0609675104 PMID: 17389372

34. Gunn JS, Ernst RK. The structure and function of *Francisella* lipopolysaccharide. Ann N Y Acad Sci. 2007; 1105:202–18. PubMed Central PMCID: PMC2742961. https://doi.org/10.1196/annals.1409.006 PMID: 17395723

35. Hajjar AM, Harvey MD, Shaffer SA, Goodlett DR, Sjostedt A, Edebro H, et al. Lack of phosphate modification in virulence and long-term protective immune responses. Infect Immun. 2012; 80(3):943–51. PubMed Central PMCID: PMC3294632. https://doi.org/10.1128/IAI.00934-06 PMID: 16982824

36. Fulop M, Webber T, Manchee R. Activation of the complement system by *Francisella* *tularensis* lipopolysaccharide. The new microbiologica. 1993; 16(2):141–7. PMID: 8510568

37. Ancuta P, Pedron T, Girard R, Sandstrom G, Chaby R. Inability of the *Francisella* lipopolysaccharide to mimic or to antagonize the induction of cell activation by endotoxins. Infect Immun. 1996; 64(6):2041–6. PubMed Central PMCID: PMC174034. PMID: 8675305

38. Raetz CR. Biochemistry of endotoxins. Annual review of biochemistry. 1990; 59:129–70. https://doi.org/10.1146/annurev.bi.59.070190.001021 PMID: 1695830

39. Phillips NJ, Schilling B, McLendon MK, Apicella MA, Gibson BW. Novel modification of lipid A of *Francisella* *tularensis*. Infect Immun. 2004; 72(9):5340–8. PubMed Central PMCID: PMC174034. PMID: 16982824

40. Vinogradov E, Perry MB, Conlan JW. Structural analysis of *Francisella* *tularensis* lipopolysaccharide. European journal of biochemistry / FEBS. 2002; 269(24):6112–8.

41. Kanistanton D, Powell DA, Hajjar AM, Pelletier MR, Cohen IE, Way SS, et al. Role of *Francisella* lipid A phosphate modification in virulence and long-term protective immune responses. Infect Immun. 2012; 80(3):943–51. PubMed Central PMCID: PMC3294632. https://doi.org/10.1128/IAI.00934-06 PMID: 2215738

42. Llewellyn AC, Zhao J, Song F, Parvathareddy J, Xu Q, Napier BA, et al. NaxD is a deacetylase required for lipid A modification and *Francisella* pathogenesis. Molecular microbiology. 2012; 86(3):611–27. PubMed Central PMCID: PMC3861722. https://doi.org/10.1111/mmi.12004 PMID: 22966934

43. Enderlin G, Morales L, Jacobs RF, Cross JT. Streptomycin and alternative agents for the treatment of tularemia: review of the literature. Clinical infectious diseases an official publication of the Infectious Diseases Society of America. 1994; 19(1):42–7. PMID: 7948556

44. Sawyer WD, Dangerfield HG, Hogge AL, Crozier D. Antibiotic prophylaxis and therapy of airborne tularemia. Bacteriological reviews. 1966; 30(3):542–50. PubMed Central PMCID: PMC378237.

45. Overholt EL, Tigges WD, Kaduli PJ, Ward MK, Charkes ND, Rene RM, et al. An analysis of forty-two cases of laboratory-acquired tularemia. Treatment with broad spectrum antibiotics. The American journal of medicine. 1961; 30:785–806. PMID: 13731776

46. Hepburn MJ, Simpson AJ. Tularemia: current diagnosis and treatment options. Expert review of anti-infective therapy. 2008; 6(2):231–40. https://doi.org/10.1586/14787210.6.2.231 PMID: 18380609
Rasmussen JA, Fletcher JR, Long ME, Allen LA, Jones BD. Characterization of F. tularensis infection.

48. Scheel O, Reiersen R, Hoel T. Treatment of tularemia with ciprofloxacin. European journal of clinical microbiology & infectious diseases official publication of the European Society of Clinical Microbiology. 1992; 11(5):447–8.

49. Johansson A, Berglund L, Gothefors L, Sjostedt A, Tarnvik A. Ciprofloxacin for treatment of tularemia in children. The Pediatric infectious disease journal. 2000; 19(5):449–53. PMID: 10819342

50. Arav-Boger R. Cat-bite tularemia in a seventeen-year-old girl treated with ciprofloxacin. The Pediatric infectious disease journal. 2000; 19(6):583–4. PMID: 10877184

51. Limaye AP, Hooper CJ. Treatment of tularemia with fluoroquinolones: two cases and review. Clinical infectious diseases an official publication of the Infectious Diseases Society of America. 1999; 29(4):922–4. https://doi.org/10.1086/520458 PMID: 10589911

52. Perez-Castrillon JL, Bachiller-Luque P, Martin-Luquero M, Mena-Martín FJ, Herrero V. Tularemia epidemic in northwestern Spain: clinical description and therapeutic response. Clinical infectious diseases an official publication of the Infectious Diseases Society of America. 2001; 33(4):573–6. https://doi.org/10.1086/322601 PMID: 11462198

53. Johansson A, Berglund L, Sjostedt A, Tarnvik A. Ciprofloxacin for treatment of tularemia. Clinical infectious diseases an official publication of the Infectious Diseases Society of America. 2001; 33(2):267–8. https://doi.org/10.1086/321825 PMID: 11418893

54. Sutera V, Caspar Y, Boisset S, Maurin M. A new dye uptake assay to test the activity of antibiotics against intracellular Francisella tularensis. Frontiers in cellular and infection microbiology. 2014; 4:36. PubMed Central PMCID: PMC3957058. https://doi.org/10.3389/fcimb.2014.00036 PMID: 24672776

55. Syrjala H, Schildt R, Raisainen S. In vitro susceptibility of Francisella tularensis to fluoroquinolones and treatment of tularemia with norfloxacin and ciprofloxacin. European journal of clinical microbiology & infectious diseases official publication of the European Society of Clinical Microbiology. 1991; 10(2):68–70.

56. Berger JM. Type II DNA topoisomerases. Current opinion in structural biology. 1998; 8(1):26–32. Epub 1998/03/31. PMID: 9519293

57. Leo E, Gould KA, Pan XS, Capranico G, Sanderson MR, Palumbo M, et al. Novel symmetric and asymmetric DNA scission determinants for Streptococcus pneumoniae topoisomerase IV and gyrase are clustered at the DNA breakage site. The Journal of biological chemistry. 2005; 280(14):14252–63. Epub 2005/01/22. https://doi.org/10.1074/jbc.M500156200 PMID: 15659402

58. Hooper DC, Wolfson JS, Ng EY, Swartz MN. Mechanisms of action of and resistance to ciprofloxacin. The American journal of medicine. 1987; 82(4A):12–20. PMID: 3034057

59. Eaves DJ, Randall LL, Gray DT, Buckley A, Woodward MJ, White AP, et al. Prevalence of mutations within the quinolone resistance-determining region of gyrA, gyrB, parC, and parE and association with antibiotic resistance in quinolone-resistant Salmonella enterica. Antimicrobial agents and chemotherapy. 2004; 48(10):4012–5. PubMed Central PMCID: PMC21866. https://doi.org/10.1128/AAC.48.10.4012-4015.2004 PMID: 15388468

60. Hooper DC. Mechanisms of action of antimicrobials: focus on fluoroquinolones. Clinical infectious diseases an official publication of the Infectious Diseases Society of America. 2001; 32 Suppl 1:S9–S15. https://doi.org/10.1086/321825 PMID: 11462198

61. Wolfson JS, Hooper DC. Fluoroquinolone antimicrobial agents. Clinical microbiology reviews. 1989; 2(4):378–424. PubMed Central PMCID: PMC358131. PMID: 2680058

62. Meredith TC, Woodard RW. Escherichia coli YrbH is a D-arabinose 5-phosphate isomerase. The Journal of biological chemistry. 2003; 278(35):32771–7. https://doi.org/10.1074/jbc.M303661200 PMID: 12805358

63. Apicella MA, Post DM, Fowler AC, Jones BD, Rasmussen JA, Hunt JR, et al. Identification, characterization and immunogenicity of an O-antigen capsular polysaccharide of Francisella tularensis. PLoS One. 2010; 5(7):e11060. PubMed Central PMCID: PMC2897883. https://doi.org/10.1371/journal.pone.0011060 PMID: 20625403

64. Jones BD, Faron M, Rasmussen JA, Fletcher JR. Uncovering the components of the Francisella tularensis virulence stealth strategy. Frontiers in cellular and infection microbiology. 2014; 4:32. PubMed Central PMCID: PMC394574. https://doi.org/10.3389/fcimb.2014.00032 PMID: 24639953

65. Rasmussen JA, Fletcher JR, Long ME, Allen LA, Jones BD. Characterization of Francisella tularensis Schu S4 mutants identified from a transposon library screened for O-antigen and capsule deficiencies. Frontiers in microbiology. 2015; 6:338. PubMed Central PMCID: PMC4419852. https://doi.org/10.3389/fmicb.2015.00338 PMID: 25999917
66. Rasmussen JA, Post DM, Gibson BW, Lindemann SR, Apicella MA, Meyerholz DK, et al. *Francisella tularensis* Schu S4 lipopolysaccharide core sugar and O-antigen mutants are attenuated in a mouse model of tularemia. Infect Immun. 2014; 82(4):1523–39. PubMed Central PMCID: PMC3993386. https://doi.org/10.1128/IAI.01640-13 PMID: 24452684

67. Kim TH, Pinkham JT, Heninger SJ, Chalabaev S, Kasper DL. Genetic modification of the O-polysaccharide of *Francisella tularensis* results in an avirulent live attenuated vaccine. The Journal of infectious diseases. 2012; 205(7):1056–65. PubMed Central PMCID: PMC3295600. https://doi.org/10.1093/infdis/jir620 PMID: 21969334

68. Raynaud C, Melborn KL, Lety MA, Dubail I, Candela T, Frapy E, et al. Role of the *wbt* locus of *Francisella tularensis* in lipopolysaccharide O-antigen biogenesis and pathogenicity. Infect Immun. 2007; 75(1):536–41. PubMed Central PMCID: PMC1828372. https://doi.org/10.1128/IAI.01429-06 PMID: 17030571

69. Gallagher LA, Ramage E, Jacobs MA, Kaul R, Brittnacher M, Manoil C. A comprehensive transposon mutant library of *Francisella novicida*, a bioweapon surrogate. Proceedings of the National Academy of Sciences of the United States of America. 2007; 104(3):1009–14. PubMed Central PMCID: PMC1783355. https://doi.org/10.1073/pnas.0606713104 PMID: 17215359

70. Rodriguez SA, Yu JJ, Davis G, Arulanandam BP, Klose KE. Targeted inactivation of *Francisella tularensis* genes by group II introns. Applied and environmental microbiology. 2008; 74(9):2619–26. Epub 2008/03/04. https://doi.org/10.1128/AEM.02905-07 PMID: 18310413

71. LoVullo ED, Sherrill LA, Pavelka MS Jr. Improved shuttle vectors for *Francisella tularensis* genetics. FEMS Microbiol Lett. 2009; 291(1):95–102. Epub 2008/12/11. https://doi.org/10.1111/j.1574-6968.2008.01440.x PMID: 19067747

72. Chamberlain RE. Evaluation of Live Tularemi a Vaccine Prepared in a Chemically Defined Medium. Applied microbiology. 1965; 13:232–5. Epub 1965/03/01. PubMed Central PMCID: PMC1058227. PMID: 14325885

73. Chin CS, Alexander DH, Marks P, Klammer AA, Drake J, Heiner C, et al. Nonhybrid, finished microbial genome assemblies from long-read SMRT sequencing data. Nature methods. 2013; 10(6):563–9. https://doi.org/10.1038/nmeth.2474 PMID: 23644548

74. Krum siek J, Arnold R, Rattei T. Gepard: a rapid and sensitive tool for creating dotplots on genome scale. Bioinformatics. 2007; 23(8):1026–8. https://doi.org/10.1093/bioinformatics/btm039 PMID: 17309896

75. Tatusova T, DiCuccio M, Badretdin A, Chetvernin V, Ciufio S, Li W. Prokaryotic Genome Annotation Pipeline. 2013. In: The NCBI Handbook [Internet] [Internet]. Bethesda (MD):: National Center for Biotechnology Information (US):. 2nd.

76. Lang mead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nature methods. 2012; 9(4):357–9. PubMed Central PMCID: PMC3322381. https://doi.org/10.1038/nmeth.1923 PMID: 22388286

77. Mc Kenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome research. 2010; 20(9):1297–303. PubMed Central PMCID: PMC2928508. https://doi.org/10.1101/gr.107524.110 PMID: 20644199

78. Cingolani P, Platts A, Wang le L, Coon M, Nguyen T, Wang L, et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnPEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly. 2012; 6(2):80–92. PubMed Central PMCID: PMC3679285. https://doi.org/10.4161/fly.19695 PMID: 22728672

79. Zhou P, Altman E, Perry MB, Li J. Study of matrix additives for sensitive analysis of lipid A by matrix-assisted laser desorption ionization mass spectrometry. Applied and environmental microbiology. 2010; 76(11):3437–43. PubMed Central PMCID: PMC2876463. https://doi.org/10.1128/AEM.03082-09 PMID: 20382818

80. Faith SA, Smith LP, Swatland AS, Reed DS. Growth conditions and environmental factors impact aerosolization but not virulence of *Francisella tularensis* infection in mice. Frontier s in cellular and infection microbiology. 2012; 2:126. PubMed Central PMCID: PMC3468843. https://doi.org/10.3389/fcimb.2012.00126 PMID: 23087911

81. Hartings JM, Roy CJ. The automated bioaerosol exposure system: preclinical platform development and a respiratory dosimetry application with nonhuman primates. Journal of pharmacological and toxicological methods. 2004; 49(1):39–55. Epub 2003/12/13. https://doi.org/10.1016/j.vascn.2003.07.001 PMID: 14670693

82. Zwietering MH, Jongenburger I, Rombouts FM, van ’t Riet K. Modeling of the bacterial growth curve. Applied and environmental microbiology. 1990; 56(6):1875–81. PubMed Central PMCID: PMC184525. PMID: 16348228
83. Nano FE, Zhang N, Cowley SC, Kloese KE, Cheung KK, Roberts MJ, et al. A Francisella tularensis pathogenicity island required for intramacrophage growth. Journal of bacteriology. 2004; 186 (19):6430–6. Epub 2004/09/18. https://doi.org/10.1128/JB.186.19.6430-6436.2004 PMID: 15375123

84. Rohmer L, Fong C, Abmayr S, Wasnick M, Larson Freeman TJ, Radey M, et al. Comparison of Francisella tularensis genomes reveals evolutionary events associated with the emergence of human pathogenic strains. Genome biology. 2007; 8(6):R102. PubMed Central PMCID: PMC2394750. https://doi.org/10.1186/gb-2007-8-6-r102 PMID: 17550600

85. Kilar A, Domyeyi A, Kocsis B. Structural characterization of bacterial lipopolysaccharides with mass spectrometry and on- and off-line separation techniques. Mass spectrometry reviews. 2013; 32(2):90–117. https://doi.org/10.1002/mas.21352 PMID: 23165926

86. Case ED, Chong A, Wehrly TD, Hansen B, Child R, Hwang S, et al. The Francisella O-antigen mediates survival in the macrophage cytosol via autophagy avoidance. Cellular microbiology. 2014; 16(6):662–77. PubMed Central PMCID: PMC4028363. https://doi.org/10.1111/cmi.12246 PMID: 24286610

87. Lindemann SR, Peng K, Long ME, Hunt JR, Apicella MA, Monack DM, et al. Francisella tularensis Schu S4 O-antigen and capsule biosynthesis gene mutants induce early cell death in human macrophages. Infect Immun. 2011; 79(2):581–94. PubMed Central PMCID: PMC3028865. https://doi.org/10.1128/IAI.00863-10 PMID: 21578861

88. Conlan JW, Chen W, Shen H, Webb A, Kuo Lee R. Experimental tularemia in mice challenged by aerosol or intradermally with virulent strains of Francisella tularensis: bacteriologic and histopathologic studies. Microb Pathog. 2003; 34(5):239–48. Epub 2003/06/07. PMID: 12723472

89. Su J, Asare R, Yang J, Nair MK, Mazurkiewicz JE, Abu-Kwaik Y, et al. The Francisella tularensis flagellar Locus is Required for Intracellular Growth of Francisella tularensis LVS. Frontiers in microbiology. 2011; 2:83. PubMed Central PMCID: PMC3128946. https://doi.org/10.3389/fmicb.2011.00083 PMID: 21747799

90. Su J, Yang J, Zhao D, Kawula TH, Banas JA, Zhang JR. Genome-wide identification of Francisella tularensis virulence determinants. Infect Immun. 2007; 75(12):3945–52. PubMed Central PMCID: PMC1932672. https://doi.org/10.1128/IAI.01505-06 PMID: 17420240

91. Twine S, Bystrom M, Chen W, Forsman M, Golovliov I, Johansson A, et al. A mutant of Francisella tularensis strain SCHU S4 lacking the ability to express a 58-kilodalton protein is attenuated for virulence and is an effective live vaccine. Infect Immun. 2006; 73(12):8345–52. PubMed Central PMCID: PMC1307091. https://doi.org/10.1128/IAI.73.12.8345-8352.2006 PMID: 16299332

92. Salomonsson S, Kuoppa K, Forslund AL, Zingmark C, Golovliov I, Sjostedt A, et al. Reintroduction of two deleted virulence loci restores full virulence to the live vaccine strain of Francisella tularensis. Infect Immun. 2009; 77(8):3424–31. PubMed Central PMCID: PMC2715654. https://doi.org/10.1128/IAI.00196-09 PMID: 19506014

93. Wen L, Chmielewski JN, Bohn KC, Huang JK, Timsina YN, Kodali P, et al. Functional expression of Francisella tularensis FabH and FabI, potential antibacterial targets. Protein expression and purification. 2009; 65(1):83–91. https://doi.org/10.1016/j.pep.2008.11.011 PMID: 19095065

94. Parsons JB, Rock CO. Bacterial lipids: metabolism and membrane homeostasis. Progress in lipid research. 2013; 52(3):249–76. PubMed Central PMCID: PMC3665635. https://doi.org/10.1016/j.plipres.2013.02.002 PMID: 23500459

95. Huntley JF, Conley PG, Hagman KE, Norgard MV. Characterization of Francisella tularensis outer membrane proteins. Journal of bacteriology. 2007; 189(2):561–74. PubMed Central PMCID: PMC1797401. https://doi.org/10.1128/JB.01505-06 PMID: 17114266

96. Wehrly TD, Chong A, Virtanen TK, Sturdevant DE, Child R, Edwards JA, et al. Intracellular biology and virulence determinants of Francisella tularensis revealed by transcriptional profiling inside macrophages. Cellular microbiology. 2009; 11(7):1128–50. PubMed Central PMCID: PMC2746821. https://doi.org/10.1111/j.1462-5822.2009.01316.x PMID: 19389004

97. Thomas RM, Titball RW, Oyston PC, Griffin K, Waters E, Hitchen PG, et al. The immunologically distinct O antigens from Francisella tularensis subspecies tularensis and Francisella novicida are both virulence determinants and protective antigens. Infect Immun. 2007; 75(1):371–8. PubMed Central PMCID: PMC1828428. https://doi.org/10.1128/IAI.01241-06 PMID: 17074846

98. Maier TM, Casey MS, Becker RH, Dorsey CW, Glass EM, Maltsev N, et al. Identification of Francisella tularensis Himar1-based transposon mutants defective for replication in macrophages. Infect Immun. 2007; 75(11):5376–89. PubMed Central PMCID: PMC2168294. https://doi.org/10.1128/IAI.00238-07 PMID: 17682043

99. Li J, Ryder C, Mandal M, Ahmed F, Azadi P, Snyder DS, et al. Attenuation and protective efficacy of an O-antigen-deficient mutant of Francisella tularensis LVS. Microbiology. 2007; 153(Pt 9):3141–53. https://doi.org/10.1099/mic.0.2007/006460-0 PMID: 17768257
100. Okan NA, Chalabae v S, Kim TH, Fink A, Ross RA, Kasper DL. Kdo hydrolase is required for Francisella tularensis virulence and evasion of TLR2-mediated innate immunity. mBio. 2013; 4(1):e00638–12. PubMed Central PMCID: PMC3573668. https://doi.org/10.1128/mBio.00638-12 PMID: 23404403

101. Sebastian S, Dillon ST, Lynch JG, Blalock LT, Balon E, Lee KT, et al. A defined O-antigen polysaccharide mutant of Francisella tularensis live vaccine strain has attenuated virulence while retaining its protective capacity. Infect Immun. 2007; 75(5):2591–602. Epub 2007/02/14. https://doi.org/10.1128/IAI.01789-06 PMID: 17296751

102. Yep A, Sorenson RJ, Wilson MR, Showalter HD, Larsen SD, Keller PR, et al. Enediol mimics as inhibitors of the D-arabinose 5-phosphate isomerase (KdsD) from Francisella tularensis. Bioorganic & medicinal chemistry letters. 2011; 21(9):2679–82.

103. Meredith TC, Woodard RW. Identification of GutQ from Escherichia coli as a D-arabinose 5-phosphate isomerase. Journal of bacteriology. 2005; 187(20):6936–42. PubMed Central PMCID: PMC1251629. https://doi.org/10.1128/JB.187.20.6936-6942.2005 PMID: 16199563

104. Gourlay LJ, Sommaruga S, Nardini M, Sperandeo P, Deho G, Polissi A, et al. Probing the active site of the sugar isomerase domain from E. coli arabinose-5-phosphate isomerase via X-ray crystallography. Protein science a publication of the Protein Society. 2010; 19(12):2430–9. PubMed Central PMCID: PMC3009410. https://doi.org/10.1002/pro.525 PMID: 20954237

105. Sommaruga S, Gioia LD, Tortora P, Polissi A. Structure prediction and functional analysis of KdsD, an enzyme involved in lipopolysaccharide biosynthesis. Biochemical and biophysical research communications. 2009; 388(2):222–7. https://doi.org/10.1016/j.bbrc.2009.07.154 PMID: 19664604